

510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY

A. 510(k) Number:

K133605

B. Purpose for Submission:

To obtain a Substantial Equivalence Determination for a new 510(k) application for the BD MAX™ MRSA XT assay on the BD MAX™ System.

C. Measurand:

Target DNA sequences for

- (1) SCCmec/orfX junction area of methicillin-resistant *Staphylococcus aureus* (i.e., MREJ for SCCmec Right Extremity Junction). The BD MAX™ MRSA XT assay is designed to detect MREJ types i, ii, iii, iv, v, vi, vii, ix, xiii, xiv, and xxi; and
- (2) mecA and mecC genes for methicillin resistance.

D. Type of Test:

Qualitative real-time polymerase chain reaction (PCR) assay for the amplification and detection of methicillin-resistant *Staphylococcus aureus* (MRSA) DNA.

E. Applicant:

GeneOhm Sciences Canada, Inc. (BD Diagnostics)

F. Proprietary and Established Names:

BD MAX™ MRSA XT
BD MAX™ System

G. Regulatory Information:

1. Regulation section:

21 CFR section 866.1640, Antimicrobial Susceptibility Test Powder

2. Classification:

Class II

3. Product code(s):
NQX - System, Nucleic acid amplification test, DNA, methicillin resistant
Staphylococcus aureus, Direct specimen

OOI - Real time nucleic acid amplification system

4. Panel:

Microbiology (83)

H. Intended Use:

1. Intended use(s):

The BD MAX™ MRSA XT assay performed on the BD MAX™ System is an automated qualitative *in vitro* diagnostic test for the direct detection of methicillin-resistant *Staphylococcus aureus* (MRSA) DNA from nasal swabs in patients at risk for nasal colonization. The test utilizes real-time polymerase chain reaction (PCR) for the amplification of MRSA DNA and fluorogenic target-specific hybridization probes for the detection of the amplified DNA. The BD MAX™ MRSA XT assay is intended to aid in the prevention and control of MRSA infections in healthcare settings. It is not intended to diagnose MRSA infections nor guide or monitor treatment for MRSA infections. A negative result does not preclude nasal colonization. Concomitant cultures are necessary to recover organisms for epidemiological typing or for further susceptibility testing.

2. Indication(s) for use:

Same as Intended Use

3. Special conditions for use statement(s):

For prescription use only

4. Special instrument requirements:

The BD MAX™ System

I. Device Description:

The BD MAX™ System and the BD MAX™ MRSA XT assay are comprised of an instrument with associated hardware and accessories, disposable microfluidic cartridges, real-time PCR master mixes, unitized reagent strips, extraction reagents, and sample buffer tubes. The instrument automates sample preparation including target lysis, DNA extraction and concentration, reagent rehydration, and target nucleic acid amplification and detection using real-time PCR. The assay includes a Sample Processing Control (SPC) that is present in the Extraction Tube. The SPC monitors DNA extraction steps, thermal cycling steps,

reagent integrity and the presence of inhibitory substances. The BD MAX™ System software automatically interprets test results.

The real-time PCR master mix includes 13 different primers (nine primers for *SCCmec/orfX* junction, two primers for *mecA*, and two primers for *mecC*) and four different molecular probes (two probes for 11 MREJ types, one probe for *mecA*, and one probe for *mecC*) for the detection of methicillin-resistant *Staphylococcus aureus* (MRSA) DNA; two primers and one molecular probe for the Sample Processing Control (SPC). In addition, the real-time PCR master mix also includes two primers and one molecular probe (VIC labeled) for the *Staphylococcus aureus nuc* gene encoding a thermostable nuclease. However, the VIC channel signal is only utilized in a different assay, the BD MAX™ StaphSR (K132822), and is not utilized by the BD MAX™ MRSA XT assay definition file for reporting MRSA results.

Brief Explanation of the Procedure

A nasal specimen is collected and transported to the laboratory using a recommended swab collection and transport system. The swab is placed in a BD MAX™ MRSA XT Sample Buffer Tube. The Sample Buffer Tube is vortexed to release cells from the swab into the buffer. The Sample Buffer Tube is placed into the BD MAX™ System and the following automated procedures occur: The bacterial cells are lysed, DNA is extracted on magnetic beads and concentrated, and then an aliquot of the eluted DNA is added to PCR reagents which contain the MRSA- specific primers used to amplify the genetic targets, if present. The assay also includes a Sample Processing Control (SPC). The SPC is present in the Extraction Tube and undergoes the extraction, concentration and amplification steps to monitor for inhibitory substances as well as process inefficiency due to instrument or reagent failure. No operator intervention is necessary once the clinical sample and reagent strip are loaded into the BD MAX™ System. The BD MAX™ System automates sample lysis, DNA extraction and concentration, reagent rehydration, nucleic acid amplification and detection of the target nucleic acid sequence using real-time polymerase chain reaction (PCR). Amplified targets are detected with hydrolysis probes labeled with quenched fluorophores. The amplification, detection and interpretation of the signals are done automatically by the BD MAX™ System.

Reagents

Contents	Quantity
BD MAX™ MRSA XT Master Mix (C7) <i>Dried PCR Master Mix containing polymerase, nucleotides and specific molecular probes and primers along with Sample Processing Control-specific molecular probe.</i>	24 tests
BD MAX™ MRSA XT Reagent Strip <i>Unitized Reagent strip containing all liquid reagents and disposable pipette tips necessary for specimen processing and DNA extraction.</i>	24 tests
BD MAX™ MRSA XT Extraction Tube (B8) <i>Dried extraction reagent containing DNA magnetic affinity beads, Achromopeptidase and Sample Processing Control</i>	24 tests
BD MAX™ MRSA XT Sample Buffer Tube <i>(with 25 septum caps)</i>	24 tests

Equipment and Materials Required But Not Provided

- BBL™ CultureSwab™ Liquid Stuart single or double swab (Becton Dickinson catalogue no. 220099 or 220109), Copan (Venturi) Transystem® Liquid Stuart single or double swab (Copan, catalogue no. 141C or 139C)
- VWR Multi-Tube Vortexer (VWR catalog no. 58816-115)
- NALGENE® Cryogenic Vial Holder (VWR, catalog no. 66008-783)
- Disposable gloves, powderless
- Sterile scissors (optional)
- Sterile Gauze
- Stopwatch or timer
- BD MAX™ PCR Cartridges (BD Diagnostic Systems catalogue no. 437519)

Quality Control

Quality control procedures monitor the performance of the assay. Laboratories must establish the number, type and frequency of testing control materials according to guidelines or requirements of local, provincial, state and/country regulations or accreditation organizations.

1. An External Positive Control is intended to monitor for substantial reagent failure while an External Negative Control is used to detect reagent or environmental contamination (or carry-over) from other specimens or MRSA amplicons. External Control materials are not provided by BD. Various types of External Controls are recommended to allow the user to select the most appropriate control for their laboratory quality control program:
 - Commercially available control materials [e.g., a reference MRSA strain (ATCC 43300) can be used as positive controls. *Staphylococcus epidermidis* strain (e.g., ATCC 12228) can be used as negative control.].
 - Previously characterized specimens known to be positive or negative for MRSA.
2. One (1) External Positive Control and one (1) External Negative Control should be run daily until adequate process validation is achieved on the BD MAX™ System. Reduced frequency of control testing should be based on a protocol and data as determined by the individual laboratory.
3. An External Negative Control that yields a positive test result is indicative of a specimen handling and/or contamination problem. Review the specimen handling technique to avoid mix-up and/or contamination. An External Positive Control that yields a negative result is indicative of a specimen handling/preparation problem. Review the specimen handling/preparation technique.
4. An External Control that yields an Unresolved, Indeterminate or Incomplete test result is indicative of a reagent or a BD MAX™ System failure. Check the BD MAX™ System and monitor for any error messages. If the problem persists, use reagents from an unopened pouch or use a new BD MAX™ MRSA XT assay kit.

Note: External Positive and Negative Controls are not used by the BD MAX™ System software for the purpose of sample test result interpretation. External Controls are treated as if they were patient samples.
5. Each BD MAX™ MRSA XT assay Extraction Tube contains a Sample Processing Control (SPC) which is a plasmid containing a synthetic target DNA sequence. The SPC

will be extracted, eluted and amplified along with any DNA present in the processed specimen. The SPC monitors the efficiency of DNA capture, washing and elution during the sample processing steps, as well as the efficiency of DNA amplification and detection during PCR analysis. If the SPC result fails to meet the acceptance criteria for a negative specimen, the result will be reported as Unresolved. An Unresolved result is indicative of specimen-associated inhibition or reagent failure. Repeat any specimen reported as “Unresolved”.

Results Interpretation

The BD MAX™ System software automatically interprets test results. A test result may be called as MRSA NEG (negative), MRSA POS (MRSA positive), or MRSA UNR (Unresolved) based on the amplification status of the targets and of the Sample Processing Control. IND (Indeterminate) or INC (Incomplete) results are due to BD MAX™ System failure. Results interpretation is based on the following decision algorithm:

Assay Result Reported	Interpretation of Result
MRSA POS	MRSA DNA detected
MRSA NEG	No MRSA DNA detected
MRSA UNR	No target amplification; no SPC amplification
IND	Indeterminate due to BD MAX™ System failure (with Warning or Error Codes)
INC	Incomplete Run (with Warning or Error Codes)

MRSA POS (MRSA DNA detected)

- Fluorescence signal is detected for both MREJ (*S. aureus* specific) and *mecA/mecC* targets; and,
- The SPC is ignored since MRSA target amplification overrides this control.

MRSA NEG (No MRSA DNA detected)

- Fluorescence signal is not detected by the BD MAX™ MRSA XT assay for any target (*mecA/mecC* and MREJ targets) and fluorescence signal is detected for the SPC; or,
- Fluorescence signal is detected for the *mecA/mecC* gene only [the *mecA* and *mecC* genes are not unique to *S. aureus* species and can be found in other bacterial genera (e.g., *S. epidermidis*)]; or
- Fluorescence signal is detected for MREJ only (*mecA* or *mecC* gene drop-out).

MRSA UNR (Unresolved result, No Target and SPC Amplification)

- Fluorescence signal not detected for *mecA/mecC* and MREJ targets; and,
- Fluorescence signal not detected for the SPC (Inhibitory specimen or reagent failure).

IND (Indeterminate result)

- BD MAX™ System failure with Warning or Error Codes.

INC (Incomplete run)

- BD MAX™ System failure with Warning or Error Codes.

J. Substantial Equivalence Information:

1. Predicate device name(s):

BD MAX™ MRSA Assay

2. Predicate 510(k) number(s):

K120138

3. Comparison with predicates:

Similarities and Differences		
Item	Device	Predicate
	BD MAX™ MRSA XT (K133605)	BD MAX™ MRSA Assay (K120138)
Intended Use	The BD MAX™ MRSA XT assay performed on the BD MAX™ System is an automated qualitative <i>in vitro</i> diagnostic test for the direct detection of methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) DNA from nasal swabs in patients at risk for nasal colonization. The test utilizes real-time polymerase chain reaction (PCR) for the amplification of MRSA DNA and fluorogenic target-specific hybridization probes for the detection of the amplified DNA. The BD MAX™ MRSA XT assay is intended to aid in the prevention and control of MRSA infections in healthcare settings. It is not intended to diagnose MRSA infections nor guide or monitor treatment for MRSA infections. A negative result does not preclude nasal colonization. Concomitant cultures are necessary to recover organisms for epidemiological typing or for further susceptibility testing.	Same
Specimen type	Nasal swabs	Same
Assay Format	Amplification: PCR Detection: Fluorogenic target-specific hybridization	Same
Mode of Detection for Methicillin Resistance in <i>S. aureus</i>	Presence of SCCmec cassette at <i>orfX</i> junction (specific to <i>S. aureus</i>) and <i>mecA</i> or <i>mecC</i> genes	Presence of SCCmec cassette at <i>orfX</i> junction (specific to <i>S. aureus</i>)
Interpretation of Test Results	Automated (Diagnostic software of BD MAX™ System)	Same
Analysis Platform	BD MAX™ System	Same
PCR Sample Preparation	Automated by the BD MAX™ System	Same
Detection Probes	TaqMan® Probe	Same

Similarities and Differences		
Item	Device	Predicate
	BD MAX™ MRSA XT (K133605)	BD MAX™ MRSA Assay (K120138)
Assay Controls	Specimen Processing Control (SPC)	Same

K. Standard/Guidance Document Referenced (if applicable):

Establishing the Performance Characteristics of Nucleic Acid-Based *In vitro* Diagnostic Devices for the Detection and Differentiation of Methicillin-Resistant *Staphylococcus aureus* (MRSA) and *Staphylococcus aureus* (SA). Draft Guidance for Industry and Food and Drug Administration Staff. Document issued on: January 5, 2011

L. Test Principle:

The BD MAX™ System uses a combination of lytic and extraction reagents to perform cell lysis and DNA extraction. Following enzymatic cell lysis at elevated temperature, the released nucleic acids are captured by magnetic affinity beads. The beads with the bound nucleic acids are washed and the nucleic acids are eluted by heat in Elution Buffer. Eluted DNA is neutralized with Neutralization Buffer and transferred to the Master Mix Tube to rehydrate the PCR reagents. The reconstituted amplification reagent is dispensed into the BD MAX™ PCR Cartridge. Microvalves in the BD MAX™ PCR Cartridge are sealed by the system prior to initiating PCR to prevent evaporation and amplicon contamination.

The amplified DNA targets are detected using hydrolysis (TaqMan®) probes labeled at one end with a fluorescent reporter dye (fluorophore) and at the other end with a quencher moiety. Probes labeled with different fluorophores are used to detect a specific amplicon in the SCCmec right- extremity junction (MREJ), the genes for methicillin resistance *mecA* and *mecC*, and SPC amplicons in three different optical channels of the BD MAX™ System: MREJ amplicons are detected in the FAM channel (475/520), *mecA* and *mecC* amplicons are detected in the ROX channel (585/630), and SPC amplicons are detected in the Cy5.5 channel (680/715). When the probes are in their native state, the fluorescence of the fluorophore is quenched due to its proximity to the quencher. However, in the presence of target DNA, the probes hybridize to their complementary sequences and are hydrolyzed by the 5'-3' exonuclease activity of the DNA polymerase as it synthesizes the nascent strand along the DNA template. As a result, the fluorophores are separated from the quencher molecules and fluorescence is emitted. The amount of fluorescence detected in the three optical channels used for the BD MAX™ MRSA TX assay is directly proportional to the quantity of the corresponding probe that is hydrolyzed. The BD MAX™ System measures these signals at the end of each amplification cycle, and interprets the data to provide a result.

M. Performance Characteristics (if/when applicable):

1. Analytical performance:

a. *Precision/Reproducibility:*

Precision Study

Within-laboratory precision was evaluated for the BD MAX™ MRSA XT assay at one site. This study was performed in the framework of BD MAX™ StaphSR assay (K132822). The results from the BD MAX™ StaphSR assay were re-analyzed in the context of the BD MAX™ MRSA XT assay, considering MRSA as the only target to be reported.

The precision panel consisted of four categories near the LoD (i.e., Moderate Positive MRSA, Low Positive MRSA, High Negative MRSA, and True Negative). Each specimen contained simulated nasal matrix (2% EMD or 5% Sigma-Aldrich w/v Mucin, 5% v/v Whole Blood, 0.8% v/v NaCl, Saline, and 0.00002% w/v Human Genomic DNA. Refer to the “Nasal Matrix and Simulated Nasal Matrix Equivalency Study” section of this decision summary for details). The MRSA strains used were *Staphylococcus aureus* ATCC 43300 (MREJ type ii) and a *Staphylococcus aureus* strain obtained from a private collection (MREJ type vii). The negative strain used in the panels was *Staphylococcus epidermidis* ATCC 14990). Bacterial strains were suspended in the simulated nasal matrix described above at the targeted concentrations. Bacterial cell numbers in the suspensions were verified by colony counts. The bacterial suspensions were divided into 82.5 ul aliquots and frozen at -80°C prior to testing. At the testing site, aliquots were thawed on a cooling block, vortexed, and spun at low speed. The contents of each aliquot were completely absorbed onto a sterile dry swab. The swab was then transferred directly into a Sample Buffer Tube (SBT) and processed according to the BD MAX™ MRSA XT assay instructions for use.

The bacterial strains were tested as follows:

- Moderate Positive (MP) MRSA (MREJ ii): ≥ 2 and $\leq 5 \times \text{LoD}$
- Low Positive (LP) MRSA (MREJ ii): ≥ 1 and $< 2 \times \text{LoD}$
- Low Positive (LP) MRSA (MREJ vii): ≥ 1 and $< 2 \times \text{LoD}$
- High Negative (HN) MRSA (MREJ ii): $< 1 \times \text{LoD}$
- True negative (TN): Negative specimens (no target)

Testing was performed in duplicate, over 12 days, with two runs per day, by two different technologists (2 replicates/run/day x 2 runs/day by two different technologists x 12 days = 48 data points for each panel member). Precision study results for TN, MP, LP, and HN MRSA samples demonstrated 100% (48/48, 95% CI, 92.6% - 100%), 100% (48/48, 95% CI, 92.6% - 100%), 97.9% (94/96, 95% CI, 92.7% - 99.4%) and 60.4% (29/48, 95% CI, 46.3% - 73.0%) agreement with expected result (i.e., negative for TN and HN, positive for MP and LP), respectively.

The precision study results met the pre-defined acceptance criteria for LP, MP, and TN samples (i.e., LP overall correct percentage of approximately 95% with 95% CI;

MP overall correct percentage of approximately 100% with 95% CI; TN overall correct percentage of approximately 100% with 95% CI). No specific acceptance criteria were defined for the HN samples.

Reproducibility Study

The reproducibility study was performed using the same sample categories and testing procedures as defined above for the Precision Study. This study was also performed in the framework of BD MAX™ StaphSR assay (K132822). The results from the BD MAX™ StaphSR assay were re-analyzed in the context of the BD MAX™ MRSA XT assay, considering MRSA as the only target to be reported.

Samples in each category were tested in triplicate, on five distinct days, wherein each day two runs were tested by two different technologists, at three clinical sites using one lot of reagents (Site-to-Site) (3 replicates/run/day x 2 runs/day by two different technologists/per site x 5 days x 3 sites = 90 data points for each panel member). One of these three clinical sites participated in an extended study where two additional lots of reagents were tested in 10 additional days (Lot-to-Lot) (3 replicates/run/day x 2 runs/day by two different technologists/per site x 5 days/per Lot x 3 Lots = 90 data points for each panel member).

For Site-to-Site Reproducibility, the overall percent agreement with expected result (i.e., negative for TN and HN, positive for MP and LP) was 100% (90/90, 95% CI, 95.9% - 100%) for MRSA MP and TN categories; 96.7% (174/180, 95% CI, 92.9% - 98.5%) for MRSA LP; and 63.3% (57/90, 95% CI, 53.0% - 72.6%) for MRSA HN.

Table 1: Site-To-Site Reproducibility Study Qualitative Results Using One Lot of the BD MAX™ MRSA XT Assay

Category	SITE						Overall Percent Agreement and 95% CI	
	Site 1		Site 2		Site 3			
	Percent Agreement	Count	Percent Agreement	Count	Percent Agreement	Count		
HN ¹ MRSA	60.0%	18/30	66.7%	20/30	63.3%	19/30	63.3% (57/90)	(53.0%, 72.6%)
LP MRSA	95.0%	57/60	98.3%	59/60	96.7%	58/60	96.7% (174/180)	(92.9%, 98.5%)
MP MRSA	100.0%	30/30	100.0%	30/30	100.0%	30/30	100.0% (90/90)	(95.9%, 100.0%)
TN ¹	100.0%	30/30	100.0%	30/30	100.0%	30/30	100.0% (90/90)	(95.9%, 100.0%)

¹Percent Agreement correlates to the percent of negative results.

End Point (EP) and Second Derivative Peak Abscissa (SDPA), two underlying numerical values used to determine a final assay result, were selected as additional means of assessing assay reproducibility.

Table 2: Site-to-Site Reproducibility Study Underlying Numerical Results Across Sites, Days, Runs, and Replicates Using One Lot, for MREJ Target with MREJ Types Pooled (FAM Channel)¹

Category		HN MRSA	LP MRSA	MP MRSA
EP	N	33	174	90
	Mean	639	965	993
	Within Run	SD	309.82	344.38
		%CV	48.5%	35.7%
	Between Run within Day	SD	166.88	63.09
		%CV	0.0%	17.3%
	Between Day within Site	SD	0.00	0.00
		%CV	0.0%	0.0%
	Between Site	SD	208.85	348.35
		%CV	32.7%	36.1%
	Overall	SD	373.64	517.49
		%CV	58.5%	53.7%
SDPA	N	33	174	90
	Mean	33.5	31.1	30.7
	Within Run	SD	0.71	1.03
		%CV	2.1%	3.3%
	Between Run within Day	SD	0.00	0.00
		%CV	0.0%	0.0%
	Between Day within Site	SD	0.00	0.14
		%CV	0.0%	0.5%
	Between Site	SD	0.10	0.17
		%CV	0.3%	0.6%
	Overall	SD	0.72	1.05
		%CV	2.2%	3.4%

¹Values shown are those obtained for the MREJ target in the samples that gave a MRSA POS result.

Table 3: Site-to-Site Reproducibility Study Underlying Numerical Results Across Sites, Days, Runs, and Replicates Using One Lot, for *mecA/mecC* Target with MREJ Types Pooled (ROX Channel)¹

Category		HN MRSA	LP MRSA	MP MRSA
EP	N	33	174	90
	Mean	1723	2583	2703
	Within Run	SD	456.44	621.52
		%CV	26.5%	24.1%
	Between Run within Day	SD	143.99	240.76
		%CV	8.4%	9.3%
	Between Day within Site	SD	199.57	0.00
		%CV	11.6%	0.0%
	Between Site	SD	510.53	558.35
		%CV	29.6%	21.6%
	Overall	SD	727.70	869.49
		%CV	42.2%	33.7%
SDPA	N	33	174	90
	Mean	35.1	31.8	31.1
	Within Run	SD	1.08	1.39
		%CV	3.1%	4.4%
	Between Run within Day	SD	0.00	0.23
		%CV	0.0%	0.7%
	Between Day within Site	SD	0.00	0.21
		%CV	0.0%	0.7%
	Between Site	SD	0.41	0.00
		%CV	1.2%	0.0%
	Overall	SD	1.16	1.42
		%CV	3.3%	4.5%

¹Values shown are those obtained for the *mecA/mecC* target in the samples that gave a MRSA POS result.

Table 4: Site-to-Site Reproducibility Study Underlying Numerical Results Across Sites, Days, Runs, and Replicates Using One Lot, Sample Processing Control Value (Cy5.5 Channel)¹

Category		LP MRSA	HN MRSA	TN
EP	N	6	57	90
	Mean	2068	3149	2968
	Within Run	SD	1141.35	901.46
		%CV	36.2%	30.4%
	Between Run within Day	SD	0.00	0.00
		%CV	0.0%	0.0%
	Between Day within Site	SD	0.00	0.00
		%CV	0.0%	0.0%
	Between Site	SD	161.90	0.00
		%CV	5.1%	0.0%
	Overall	SD	1152.78	901.46
		%CV	36.6%	30.4%
SDPA	N	6	57	90
	Mean	30.1	30.3	30.2
	Within Run	SD	0.53	0.51
		%CV	1.8%	1.7%
	Between Run within Day	SD	0.00	0.13
		%CV	0.0%	0.4%
	Between Day within Site	SD	0.17	0.08
		%CV	0.6%	0.3%
	Between Site	SD	0.49	0.35
		%CV	1.6%	1.1%
	Overall	SD	0.74	0.63
		%CV	2.5%	2.1%

¹Calculated for the Specimen Processing Control of the samples that gave a MRSA NEG result.

For Lot-to-Lot Reproducibility, the overall percent agreement with expected result (i.e., negative for TN and HN, positive for MP and LP) was 100% (90/90, 95% CI, 95.9% - 100%) for MRSA MP and TN categories; 96.7% (174/180, 95% CI, 92.9% - 98.5%) for MRSA LP; and 61.1% (55/90, 95% CI, 50.8% - 70.5%) for MRSA HN.

Table 5: Lot-To-Lot Reproducibility Study Results using Three Lots of the BD MAXTM MRSA XT Assay

Category	LOT						Overall Percent Agreement and 95% CI	
	Lot 1		Lot 2		Lot 3			
	Percent Agreement	Count	Percent Agreement	Count	Percent Agreement	Count		
HN ¹ MRSA	63.3%	19/30	63.3%	19/30	56.7%	17/30	61.1% (55/90)	(50.8%, 70.5%)
LP MRSA	96.7%	58/60	96.7%	58/60	96.7%	58/60	96.7% (174/180)	(92.9%, 98.5%)
MP MRSA	100.0%	30/30	100.0%	30/30	100.0%	30/30	100.0% (90/90)	(95.9%, 100.0%)
TN	100.0%	30/30	100.0%	30/30	100.0%	30/30	100.0% (90/90)	(95.9%, 100.0%)

¹Percent Agreement correlates to the percent of negative results.

End Point (EP) and Second Derivative Peak Abscissa (SDPA), two underlying numerical values used to determine a final assay result, were selected as additional means of assessing assay reproducibility.

Table 6: Lot-to-Lot Reproducibility Study Underlying Numerical Results Across Lots, Days, Runs, and Replicates at One Site, for MREJ Target with MREJ Types Pooled (FAM Channel)¹

Category		HN MRSA	LP MRSA	MP MRSA
EP	N	35	174	90
	Mean	346	581	571
	Within Run	SD	131.14	200.66
		%CV	38.0%	34.6%
	Between Run within Day	SD	0.00	50.91
		%CV	0.0%	8.8%
	Between Day within Lot	SD	34.69	0.00
		%CV	10.0%	0.0%
	Between Lot	SD	0.00	52.86
		%CV	0.0%	9.3%
	Overall	SD	135.65	203.69
		%CV	39.3%	35.7%
SDPA	N	35	174	90
	Mean	33.4	31.0	30.8
	Within Run	SD	0.60	0.94
		%CV	1.8%	3.0%
	Between Run within Day	SD	0.35	0.00
		%CV	1.1%	0.0%
	Between Day within Lot	SD	0.00	0.07
		%CV	0.0%	0.2%
	Between Lot	SD	0.20	0.03
		%CV	0.6%	0.1%
	Overall	SD	0.72	0.94
		%CV	2.2%	3.0%

¹Values shown are those obtained for the MREJ target in the samples that gave a MRSA POS result.

Table 7: Lot-to-Lot Reproducibility Study Underlying Numerical Results Across Lots, Days, Runs, and Replicates at One Site, for *mecA/mecC* Target with MREJ Types Pooled (ROX Channel)¹

Category		HN MRSA	LP MRSA	MP MRSA
EP	N	35	174	90
	Mean	1220	2041	2033
	Within Run	SD	473.47	567.63
		%CV	38.8%	27.8%
	Between Run within Day	SD	131.35	97.16
		%CV	10.8%	4.8%
	Between Day within Lot	SD	154.33	0.00
		%CV	12.7%	0.0%
	Between Lot	SD	276.63	78.75
		%CV	22.7%	3.9%
	Overall	SD	584.61	581.25
		%CV	47.9%	28.5%
SDPA	N	35	174	90
	Mean	35.0	31.7	31.1
	Within Run	SD	0.90	1.36
		%CV	2.6%	4.3%
	Between Run within Day	SD	0.45	0.00
		%CV	1.3%	0.0%
	Between Day within Lot	SD	0.00	0.00
		%CV	0.0%	0.0%
	Between Lot	SD	0.55	0.00
		%CV	1.6%	0.0%
	Overall	SD	1.15	1.36
		%CV	3.3%	4.3%

¹Values shown are those obtained for the *mecA/mecC* target in the samples that gave a MRSA POS result.

Table 8: Lot-to-Lot Reproducibility Study Underlying Numerical Results Across Lots, Days, Runs, and Replicates at One Site, Sample Processing Control Value (Cy5.5 Channel)¹

Category		HN MRSA	TN
EP	N	55	90
	Mean	2799	2877
	Within Run	SD	580.44
		%CV	20.7%
	Between Run within Day	SD	0.00
		%CV	0.0%
	Between Day within Lot	SD	66.95
		%CV	2.4%
	Between Lot	SD	0.00
		%CV	0.0%
SDPA	Overall	SD	584.29
		%CV	20.9%
	N	55	90
	Mean	30.0	30.0
	Within Run	SD	0.41
		%CV	1.4%
	Between Run within Day	SD	0.00
		%CV	0.0%
	Between Day within Lot	SD	0.00
		%CV	0.0%
	Between Lot	SD	0.17
		%CV	0.6%
	Overall	SD	0.45
		%CV	1.5%

¹Calculated for the Specimen Processing Control of the samples that gave a MRSA NEG result.

The reproducibility study results met the pre-defined acceptance criteria for LP, MP, and TN samples (i.e., LP overall correct percentage of approximately 95% with 95% CI; MP overall correct percentage of approximately 100% with 95% CI; TN overall correct percentage of approximately 100% with 95% CI). No specific acceptance criteria were defined for the HN samples.

b. Linearity/assay reportable range:

Not applicable

c. Traceability, Stability, Expected values (controls, calibrators, or methods):

Controls

Positive and Negative External Controls

An External Positive Control is intended to monitor for substantial reagent failure while an External Negative Control is used to detect reagent or environmental contamination (or carry-over) from other specimens or MRSA amplicons. External Control materials are not provided by BD in the BD MAX™ MRSA XT assay. However, during the clinical trial, external controls were freshly prepared and tested per package insert with each group of samples tested on the BD MAX™ instrument.

A failed control invalidated the entire run. In the case of a failure of either or both external controls, the testing of all samples included in the run was repeated from the appropriately stored SBTs along with a new set of external controls. In cases where external controls failed again, no additional repeat testing was performed.

Refer to K132822 Decision Summary for external controls performance data generated during the prospective clinical study for the BD MAX™ StaphSR assay.

Internal Sample Processing Control (SPC)

The Sample Processing Control incorporated into each Unitized Reagent Strip (URS) is intended to monitor PCR inhibition as well as reagent integrity for each sample tested. A failed SPC renders a sample result “Unresolved” (UNR). The clinical sites were instructed to repeat all UNR samples on the next run.

Refer to K132822 Decision Summary for SPC performance data generated during the prospective clinical study for the BD MAX™ StaphSR assay.

Nasal Matrix and Simulated Nasal Matrix Equivalency Study

Negative natural clinical nasal matrix is difficult to obtain due to the high prevalence of *mecA/mecC* and *nuc* genes present in normal bacterial nasal flora, in a proportion of 60-85% and 20-30%, respectively. In order to compensate for the limited availability of negative natural clinical nasal matrix, a simulated nasal matrix was developed for the verification and validation studies of the BD MAX™ MRSA XT assay.

An analytical study was carried out to demonstrate the equivalency between the natural clinical nasal matrix and simulated nasal matrix developed. This study was performed in the framework of BD MAX™ StaphSR assay (K132822). The results from the BD MAX™ StaphSR assay were re-analyzed in the context of the BD MAX™ MRSA XT assay, considering MRSA as the only target to be reported.

The composition of the simulated nasal matrix is the following:

Table 9: Composition of the Simulated Nasal Matrix

Component	Quantity
Mucin	2% (EMD) or 5% (Sigma-Aldrich) w/v
Blood	5% v/v
Saline (0.85% NaCl)	0.8% v/v NaCl (95% Saline)
Human Genomic DNA	0.00002% w/v (200pg/ul)

Note that bovine mucin from two suppliers (EMD and Sigma-Aldrich) was used in the formulation of the simulated nasal matrix. During product development, Sigma-Aldrich was unable to supply mucin due to placing the product on backorder. Thus, the supplier was replaced by EDM. The suitable mucin concentration was determined to be 2% for the mucin from EMD and 5% for the mucin from Sigma- Aldrich. The

simulated matrix containing 5% mucin from EMD was found to be inhibitory at 5% compared to the clinical nasal matrix.

An MRSA MREJ Type ii bacterial panel (a bacterial suspension corresponding to a target concentration of 2-3X LoD, 256 CFU/swab) was used in this study. Twelve replicates of negative natural clinical nasal matrix and simulated nasal matrix (mucin from EMD or Sigma-Aldrich) in SBT were tested using five BD MAX™ instruments.

Statistical analysis was performed. The Two One-Sided Test (TOST) procedure of Schuirmann (1987) was used for assessing the equivalence of the SDPA means. Rejection of the non-equivalence hypothesis in favor of the equivalence hypothesis at a significance level of 5% occurred only if the 90% confidence interval of the mean difference was contained completely within the equivalence margins which are listed in the table below:

Table 10: Analytical Acceptability Criteria for BD MAX™ MRSA XT Assay

	Analytical Acceptability Criteria	
With and Without Simulated Nasal Matrix	FAM SDPA (Pos)	± 6%
	ROX SDPA (Pos)	± 6%
	Cy5.5 SDPA(Neg)	± 4%

Data from this study were used to perform TOST equivalency analyses for FAM mean SDPA values between clinical matrix and simulated matrix (5% and 2% mucin supplied by Sigma-Aldrich and EMD, respectively). Data from the ROX channel were not considered for the clinical matrix condition comparison, as the *mecA/mecC* genes (detected in ROX channel) are present in a normal bacterial nasal flora. However, the ROX channel was considered in the comparison of the simulated matrix composition.

The mean SDPA obtained for the simulated and natural clinical matrices in the FAM channel (5% Sigma-Aldrich mucin and 2% EMD mucin) are equivalent based on meeting the Analytical Acceptability Criteria described above. The comparison of the FAM and ROX mean SDPA of the two simulated nasal matrix composition showed that the simulated matrix containing 2% EMD mucin is also equivalent to the simulated matrix containing 5% Sigma-Aldrich mucin based on meeting the Analytical Acceptability Criteria described above.

In conclusion, this study demonstrated that both simulated nasal matrices (5% Sigma-Aldrich and 2% EMD mucin, respectively) developed for the BD MAX™ MRSA XT assay are equivalent to each other and are equivalent to negative natural clinical nasal matrix. Therefore, the simulated nasal matrices are appropriate and adequate to be used in place of natural nasal matrix for the verification and validation studies of the BD MAX™ MRSA XT assay.

Preservation of DNA on Collection Device

The preservation of amplifiable DNA on Liquid Stuart swabs was evaluated in an analytical study. This study was performed in the framework of BD MAX™ StaphSR assay (K132822). The results from the BD MAX™ StaphSR assay were re-analyzed in the context of the BD MAX™ MRSA XT assay, considering MRSA as the only target to be reported.

Twelve (12) methicillin-resistant *S. aureus* (MRSA) strains, 18 methicillin-sensitive *S. aureus* (MSSA) strains, and 30 methicillin-susceptible *Staphylococcus* sp. (MSSsp) strains were used in this study. The MRSA strains were of diverse geographical origin and included MREJ types i, ii, iii, iv, v, vi, vii, ix, xiii, xiv, and xxi. For MRSA and MSSA strains, a mix of 75 µL of simulated matrix and 7.5 ul of a bacterial suspension corresponding to a target concentration of 2-3X LoD was used to determine the preservation of amplifiable DNA on Liquid Stuart swabs. For MSSsp strains, a mix of 75 ul of simulated matrix and 7.5 ul of a bacterial suspension corresponding to a theoretical concentration of 1.30E+06 CFU/mL was tested.

Each collection (Liquid Stuart swab) was tested with 12 MRSA, 18 MSSA, and 30 MSSsp strains at baseline and under four different storage conditions using five different instruments. The Liquid Stuart swabs were used to completely absorb 82.5 µL of the relevant bacterial suspension; the swabs were then inserted into their respective transport tubes and stored under the following conditions:

- room temperature for at least 5 minutes (T=0)
- 25 ± 2°C for 48 hours
- 25 ± 2°C for 60 hours
- 2-8°C for 120 hours (5 days)
- 2-8°C for 150 hours

Samples were then analyzed with the BD MAX™ MRSA XT assay.

To be considered acceptable, the percentage of conforming results had to be equal to or greater than 95%.

The percentage of conforming results met the acceptance criteria ($\geq 95\%$), under all storage conditions, for all strains tested.

In conclusion, this analytical study demonstrated that DNA from MRSA strains absorbed on Liquid Stuart swabs is stable up to 60 hours at 25 ± 2°C and up to 150 hours at 2-8°C. DNA from MSSA and MSSsp strains absorbed on Liquid Stuart swabs gave the expected negative result up to 60 hours at 25 ± 2°C and up to 150 hours at 2-8°C.

Lysis Efficiency

The lysis efficiency characterization was presented in the BD MAX™ MRSA Assay 510(k) (K120138). A lysis efficiency of $\geq 97\%$ was obtained for the BD MAX™ MRSA Assay. Since the lysis strategy has not changed for the BD MAX™ MRSA XT assay, no new lysis efficiency analytical study was performed.

Preservation of DNA in Sample Buffer Tube (SBT)

The preservation of amplifiable DNA in Sample Buffer Tube (SBT) was evaluated in an analytical study. This study was performed in the framework of BD MAX™ StaphSR assay (K132822). The results from the BD MAX™ StaphSR assay were re-analyzed in the context of the BD MAX™ MRSA XT assay, considering MRSA as the only target to be reported.

Twelve (12) methicillin-resistant *S. aureus* (MRSA) strains, 18 methicillin-sensitive *S. aureus* (MSSA) strains, and 30 methicillin-susceptible *Staphylococcus* sp. (MSSsp) strains were used in this study. The MRSA strains were of diverse geographical origin and included MREJ types i, ii, iii, iv, v, vi, vii, ix, xiii, xiv, and xxi. For MRSA and MSSA strains, a bacterial suspension corresponding to a target concentration of 2-3X LoD was used to determine the preservation of amplifiable DNA in the SBT. For MSSsp strains, a bacterial suspension corresponding to a theoretical concentration of 1.30E+06 CFU/mL was tested.

The study was performed with 12 MRSA, 18 MSSA, and 30 MSSsp strains at baseline and under four different storage conditions using five different instruments. The Liquid Stuart swabs were used to completely absorb 75 μ L of the relevant bacterial suspension; the swabs were then inserted into their respective transport tubes for five minutes. The swabs were then broken off into SBTs (three lots) containing simulated nasal matrix. The SBTs containing the swabs were stored under the following conditions:

- room temperature for at least 5 minutes (T=0)
- $25 \pm 2^\circ\text{C}$ for 36 hours
- $25 \pm 2^\circ\text{C}$ for 45 hours
- $2-8^\circ\text{C}$ for 120 hours (5 days)
- $2-8^\circ\text{C}$ for 150 hours

Samples were then analyzed with the BD MAX™ MRSA XT assay.

To be considered acceptable, the percentage of conforming results had to be equal to or greater than 95%. Results were calculated for each time point separately.

The percentage of conforming results met the acceptance criteria ($\geq 95\%$), under all storage conditions, for all strains tested.

In conclusion, this analytical study demonstrated that DNA from MRSA strains is stable up to 45 hours at $25 \pm 2^\circ\text{C}$ and up to 150 hours at $2-8^\circ\text{C}$ after sample elution in SBT. DNA from MSSA and MSSsp strains gave the expected negative result up to 45 hours at $25 \pm 2^\circ\text{C}$ and up to 150 hours at $2-8^\circ\text{C}$ after sample elution in SBT.

Recovery of Methicillin-Resistant *S. aureus* Cells in Sample Buffer Tube

An analytical study was carried out to demonstrate that MRSA remains viable when stored 36 to 45 hours after a BD MAX™ run (3 hours at 25°C) followed by incubation at $2-8^\circ\text{C}$ in the Sample Buffer Tube (SBT). This study was performed in the framework of BD MAX™ StaphSR assay (K132822).

Three simulated nasal matrix lots were used in combination with three different lots of Sample Buffer Tubes (SBT). Three MRSA reference strains representing MREJ Type ii, iiv, and ii (PFGE USA300) were used in this study.

Cultures were prepared and diluted in order to obtain suspensions consistent with 2-3X LoD of the BD MAX™ MRSA XT assay. The concentration was confirmed by bacterial count. For each strain, 75 μL of cell suspension were distributed in 2 mL tubes and absorbed with a swab.

Six swabs were spiked by absorbing a bacterial suspension of 75 μL (3 for 36 hours and 3 for 45 hours). After the complete volume of sample was absorbed with a collection swab, each swab was reinserted into its storage device and incubated for at least five minutes at room temperature. Each swab was then broken in its respective SBT (three lots) containing simulated nasal matrix. Tubes were closed and vortexed for 1 minute. For each sample and incubation time (36 and 45 hours), a time zero point was established using 600 μL of the suspension dispensed in 2 mL tubes pre-incubation. All samples were then incubated for 3 hours at 25°C followed by 36 or 45 hours at $2-8^\circ\text{C}$.

To determine viability, two culture methods were used; direct culture and enriched culture. The direct culture was performed by plating 50 μL of samples on each of the six CHROMagar™ MRSA plates; mauve-colored colonies were considered as MRSA positive. If plates were MRSA negative after 24 hours, they were incubated for another 24 hours. The enriched culture was executed by adding 300 μL of samples in a TSB NaCl 6.5% tube. Cultures with growth were then processed by following the same steps used for the direct culture. If no growth was observed, tubes were incubated for another 24 hours at 35°C followed by the same procedure. If MRSA is isolated from three Direct Culture plates, the Enriched Culture may be halted.

MRSA viability was determined by the presence of MRSA on a minimum of one out of six CHROMagar™ MRSA plates per strain by either direct or enriched culture method.

Acceptance criteria were met all storage conditions. Growth was observed on at least one out of six CHROMagar™ MRSA plates.

In conclusion, this analytical study demonstrated that MRSA (at 2-3X LoD of the BD MAX™ MRSA XT assay) remains viable after storage of 3 hours at 25°C followed by 36 to 45-hours incubation at 2-8°C in the SBT.

Reagents Shelf Life Determination

The stability of the BD MAX™ MRSA XT assay stored at 2-8°C and $25 \pm 2^\circ\text{C}$ was evaluated in real-time. Testing was performed to determine the stability of the BD MAX™ MRSA XT kit and the lysis efficiency of the extraction tube over time.

Since the reagents are exactly the same for both the BD MAX™ StaphSR (K132822) and the BD MAX™ MRSA XT (K133605) assays, a single stability study was performed to determine the shelf life of both assays. The results from the study were analyzed in the context of the BD MAX™ MRSA XT assay, considering MRSA as the only target to be reported.

Three lots of kit components (strips, Master Mix, Sample Buffer and Extraction Tubes) were stored at 2-8°C and $25 \pm 2^\circ\text{C}$. A subset of the first lot was subjected to simulated shipping conditions prior to storage at 2-8°C and $25 \pm 2^\circ\text{C}$. Components were removed from storage at pre-determined time points for testing. Trend of the PCR metric curves (in each channel) over time was analyzed by a linear regression model and used to determine a stability breaking point. A stability breaking point is defined as time point when the confidence interval (CI) of the linear regression crosses the Allowable Drift Limits (ADL). Tolerance intervals with 95% confidence and 99.73% coverage of the means were used to set the ADL empirically. The tolerance interval assessment was based on a total sample size of 1088 for the POS PCR curve parameters (SDPA and LogEP) and on a total sample size of 978 for the NEG PCR curve parameters (SDPA and LogEP) tested at baseline ($T=0$). If no significant degradation (i.e., no stability breaking point is identified) occurred over time, the kit stability corresponds to the last tested time point.

Three lots of kit Extraction Tubes were stored at 2-8°C and $25 \pm 2^\circ\text{C}$. A subset of the first lot was subjected to simulated shipping conditions prior to storage at 2-8°C and $25 \pm 2^\circ\text{C}$. Components were removed from storage at pre-determined time points for testing. The extent of the lysis was measured by optical density and the lysis percentage was calculated. This percentage was used to determine a stability breaking point. A stability breaking point is reached when at least one out of three lots shows failed results for two consecutive time points.

Shipping simulation consisted of storage in extreme conditions variations for up to 11 days. Temperature ranged from -10°C to 40°C and humidity varied from 10% to 70-75% RH.

BD MAX™ MRSA XT kit stability and Extraction Tubes lysis efficiency tests were taken into account to determine the shelf-life but were analyzed independently. Overall kit shelf life claim is based on the least stable lot tested for the kit stability or for the lysis efficiency (*i.e.*, lot of BD MAX™ MRSA XT or lot of Extraction Tube).

To determine the shelf life of components in open pouches, a simulation of normal storage conditions at customer sites was performed as the following:

1. Sealed bags of Master Mix and Extraction Tubes were stored at $25 \pm 2^\circ\text{C}$ / $60 \pm 5\%$ RH for pre-determined periods of time prior to the initial opening of the sealed bag(s).
2. The bag(s) were then unsealed and stored at $2-8^\circ\text{C}$ and $25 \pm 2^\circ\text{C}$ / $60 \pm 5\%$ RH.
3. From this point on, bags were opened and closed every day.
4. Components stored at $2-8^\circ\text{C}$ or at $25 \pm 2^\circ\text{C}$ / $60 \pm 5\%$ RH were tested after 7, 14 and 17 days.

The stability study is currently ongoing and available real-time data supports a shelf life of up to eight months at $2-8^\circ\text{C}$ and/or $25 \pm 2^\circ\text{C}$ when Master Mix and Extraction Tubes are stored in sealed bags.

After initial bag opening and re-sealing of the pouch, real-time data supports a shelf life of seven days when Master Mix and Extraction Tubes are stored at $2-8^\circ\text{C}$ or at $25 \pm 2^\circ\text{C}$. All other kit components are stored unsealed as per kit configuration. Simulated shipping does not impact shelf life.

Un-reconstituted Reagents Stability outside of Protective Pouch

An analytical study was carried out to demonstrate the stability of the sealed reagents (Master Mix and Extraction Tube) when stored for five hours at $2-8^\circ\text{C}$ or $25 \pm 2^\circ\text{C}$ outside of the protective pouch.

This study was performed in the framework of BD MAX™ StaphSR assay (K132822). The results from the BD MAX™ StaphSR assay were re-analyzed in the context of the BD MAX™ MRSA XT assay, considering MRSA as the only target to be reported.

One methicillin-resistant *S. aureus* (MREJ type ii) strain and one methicillin-sensitive *S. aureus* strain were used in this study. Bacterial suspensions corresponding to a target concentration of 3X LoD were tested in this study. The study was performed using more than five different instruments.

The Master Mix and the Extraction Tube were stored under the following conditions:

- $25 \pm 2^\circ\text{C}$ for 5 hours
- $25 \pm 2^\circ\text{C}$ for 6.25 hours
- $2-8^\circ\text{C}$ for 5 hours
- $2-8^\circ\text{C}$ for 6.25 hours

The swabs were used to absorb 75 µL of the relevant bacterial suspension and then broken off into SBTs containing simulated nasal matrix. Samples were then analyzed with the BD MAX™ MRSA XT assay.

To be considered acceptable, the percentage of conforming results had to be equal to or greater than 95%.

The percentage of conforming results met the acceptance criteria ($\geq 95\%$), under all storage conditions, for all strains tested.

In conclusion, this analytical study demonstrated that un-reconstituted sealed reagents (Master Mix and Extraction Tube) outside of the protective pouch are stable when stored for up to 5 hours at $25 \pm 2^\circ\text{C}$ or at $2-8^\circ\text{C}$.

d. Detection limit:

Limit of Detection (LoD) for the BD MAX™ MRSA XT assay was determined in an analytical study. This study was performed in the framework of BD MAX™ StaphSR assay (K132822). The results from the BD MAX™ StaphSR assay were re-analyzed in the context of the BD MAX™ MRSA XT assay, considering MRSA as the only target to be reported.

Positive specimens were prepared by soaking swabs in a wide range of MRSA bacterial suspensions prepared and quantified from cultures. The tested strains included 11 MRSA strains representing 11 MREJ genotypes (i, ii, iii, iv, v, vi, vii, ix, xiii, xiv and xxi) corresponding to five SCCmec types (I, II, III, IV and XI). The swabs were then eluted in simulated nasal matrix (Refer to the “Nasal Matrix and Simulated Nasal Matrix Equivalency Study” section of this decision summary for details). Each MRSA strain was tested in replicates of 24 per concentration by two different operators using three different production lots of the BD MAX™ MRSA XT assay. LoDs, defined as the lowest concentration at which 95% of all replicates tested positive, were determined using a statistically based methodology. This methodology allows determination of the LoD with a 95% confidence interval. Specifically, the LoD results were determined using a statistical linear logistic model that describes the relationship between the probability of the response and the bacterial concentration. This method models the positive response (expressed in percentage) as a function of Log (CFU/swab). The logistic model equation for the fitted curve allows the computation of the LoD by inverse prediction using the parameter estimates and their 95% confidence interval.

Table 11: Limit of Detection of MRSA Genotypes by the BD MAX™ MRSA XT Assay

MRSA Strain	MREJ Genotype	SCCmec type ¹	LoD Concentration [CFU/swab (95% CI ⁴)]
1	Type i	I	84 (49, 142)
2	Type ii	II	103 (64, 167)
3	Type iii	III	160 (93, 278)

4	Type iv	III	68 (42, 109)
5	Type v	IV	128 (73, 225)
6	Type vi	ND ²	343 (186, 632)
7	Type vii	II	219 (110, 439)
8	Type ix	ND ²	144 (82, 255)
9	Type xiii	ND ²	64 (36, 114)
10	Type xiv	ND ²	78 (48, 127)
11	Type xxi ³	XI	112 (64, 197)

¹SCCmec type does not correlate to the MREJ type as these are two different typing methods.

²ND = not determined

³mecC-containing MRSA strains (Also known as *mecA*_{LGA251} strain)

⁴Confidence Interval

e. *Analytical reactivity:*

An analytical inclusivity study was performed using a variety of MRSA strains, taking into account geographic origin, MREJ genotype (wild type and mutant), SCCmec type, Pulsed-Field Gel Electrophoresis (PFGE) type, temporal diversity and susceptibility pattern. This study was performed in the framework of BD MAX™ StaphSR assay (K132822). The results from the BD MAX™ StaphSR assay were re-analyzed in the context of the BD MAX™ MRSA XT assay, considering MRSA as the only target to be reported.

Seventy-seven (77) MRSA strains from 27 countries were tested at a concentration equivalent to 2-3X LoD in this study, including strains from public collections and from well-characterized clinical isolates, including Vancomycin-Resistant *Staphylococcus aureus* (VRSA) and Vancomycin Intermediate *Staphylococcus aureus* (VISA) strains.

Table 12: Analytical Reactivity Study Results Testing MRSA Strains at 2-3X LOD

Collection	Reference Number	Geographic Origin	MREJ Type	SCCmec Typing/ PFGE Type	Year of the Strain's Isolation/Year of Freezing	Assay Result Obtained with BD MAX™ MRSA XT Assay
ATCC	ATCC BAA-	ND	iii	USA1000	ND	MRSA POS
	ATCC BAA-42	Portugal (Lisbon)	ii	VI	1996	MRSA NEG ¹
	ATCC BAA-38	Denmark (Gentofte)	i	I	1960's	MRSA POS
	ATCC BAA-41	USA (NY city)	ii	II	1994	MRSA POS
	ATCC BAA-39	Hungary (Dunaújváros)	iii	III	1993	MRSA POS
	ATCC BAA-40	Portugal (Lisbon)	iv	III	1994	MRSA POS
	ATCC 43300	USA, Kansas	ii	II	ND	MRSA POS
	ATCC 33592	USA (NY city)	iv	III	1979	MRSA POS
Harmony Collection of European Epidemic MRSA	62305	Finland (NK)	ii mut36	IV	1990	MRSA POS
	97S99	Belgium (Brussels)	ii mut45	IV	1992	MRSA POS
	3717	Greece (Athens)	iii	III	1994	MRSA POS
	9805-01937	Sweden (Orebro)	iii mut45	ND	1998	MRSA POS
LSPQ	ID-61882	Canada	iii	III / CMRSA-	2001	MRSA POS
	ID-61880	Canada	vii	II / CMRSA-1	2001	MRSA POS
	NRS383	USA (North Carolina)	ii	II / USA200	2009	MRSA POS

NARSA	NRS385	USA (Connecticut)	ii	IV / USA500	2009	MRSA POS
	NRS715	USA (New York)	ii	II/USA600	2006	MRSA POS
	NRS386	USA (Louisiana)	ii	IV / USA700	2009	MRSA POS
	NRS686	USA (Georgia)	i	IV/IBERIAN	2006	MRSA POS
	NRS23 ⁴	USA (California)	ii	II	2000	MRSA POS
	VRS5 ³	USA (Michigan)	ii	ND	2005	MRSA POS
	NRS1 ⁴	Japan	ii	II	1996	MRSA POS
	NRS4 ⁴	USA (New Jersey)	ii	II	1997	MRSA POS
	VRS2 ³	USA (Pennsylvanie)	ii	ND	2002	MRSA POS
	VRS4 ³	USA (Michigan)	ii	ND	2005	MRSA NEG ¹
	NRS382	USA (Ohio)	ii	II / USA100	2009	MRSA POS
	NRS384	USA (Mississippi)	ii	IV / USA300	1998	MRSA POS
	NRS387	USA (Washington)	ii	IV / USA800	2009	MRSA POS
	NRS484	USA (Alaska)	ii	IV / USA1100	2009	MRSA POS
	NRS645	USA (California)	ii	IV/IBERIAN	2005	MRSA POS
	NRS123	USA (North Dakota)	ii mut36	IV / USA400	1998	MRSA POS
Well Characterized Clinical Strains	NA	USA (Baltimore)	ii	II / USA 100	ND	MRSA POS
	NA	USA (Baltimore)	iii	II / USA 100	ND	MRSA POS
	NA	ND	ii	II / USA100	2002	MRSA POS
	NA	USA (Connecticut)	ii	IV / USA300	2007	MRSA POS
	NA	USA (Connecticut)	ii	IV / USA300	2007	MRSA POS
	NA	USA (Connecticut)	ii	IV / USA300	2007	MRSA POS
	NA	USA (Connecticut)	ii	IV / USA300	2007	MRSA POS
	NA	USA (Connecticut)	ii	IV / USA300	2007	MRSA POS
	NA	USA (Connecticut)	ii mut36	IV / USA400	2007	MRSA POS
	NA	USA (Baltimore)	ii	IV / USA 800	ND	MRSA POS
	NA ⁵	France, Aix en Provence	xxi	ND	2006	MRSA POS
	NA ⁵	Denmark	xxi	ND	2005	MRSA POS
	NA	USA (Miami)	i	VIII	2002	MRSA POS
	NA	Sweden	iii	VII	ND	MRSA POS
	NA	USA, Washington,	xiii	ND	2007	MRSA POS
	NA	USA, Delaware,	xiv	ND	ND	MRSA POS
	NA	Mexico	ii	ND	2002	MRSA POS
	NA	Israel	ii	ND	2002	MRSA POS
	NA	South Africa	ii	ND	2002	MRSA POS
	NA	United Kingdom	ii mut36	ND	ND	MRSA POS
	NA	Netherlands (Den Bosch)	iii	V	2007	MRSA POS
	NA	USA (New Jersey)	iii	V	2007	MRSA POS
	NA	Italy	iii	ND	2002	MRSA POS
	NA	China (Hong Kong)	iii	ND	2002	MRSA POS
	NA	Turkey	iv	ND	2002	MRSA POS
	NA	Denmark (Copenhagen)	iv	III	2000	MRSA POS
	NA	Canada (Toronto)	v	IV	1996	MRSA POS
	NA	Australia	v	ND	2002	MRSA POS
	NA	USA	vi	ND	2007	MRSA POS
	NA	Norway	vi	ND	2007	MRSA POS
	NA	Brazil	vii	ND	2002	MRSA POS ²

	NA	Singapore	vii	ND	2002	MRSA POS
	NA	Canada (Toronto)	vii	II	2001	MRSA POS
	NA	Albania (Tirana)	vii	ND	2001	MRSA POS
	NA	USA	vi	ND	2007	MRSA POS
	NA	Poland	ix	ND	ND	MRSA POS
	NA	USA	xiii	ND	2007	MRSA POS
	NA ⁵	France	xxi	ND	2008	MRSA POS
	NA	Germany, Tübingen	xiv	ND	2008	MRSA POS
	NA	Denmark	i	I	2002	MRSA POS
	NA ⁵	United Kingdom,	xxi	ND	2009	MRSA POS
	NA ⁵	United Kingdom, England, Somerset	xxi	XI	2007	MRSA POS
	NA	Canada	iii	III	2002	MRSA POS
	NA	Canada (Québec)	v	IV	2002	MRSA POS
	NA	United Kingdom	vii	II	2002	MRSA POS
	NA	Austria	ii mut36	ND	2001	MRSA POS

¹The initial result was negative for MRSA. Both samples were repeated from the SBT and assay results are conforming (MRSA POS).

²These are the results for the repeats as the initial run gave an IND result due to a PCR heater warning.

³VRSA strains

⁴VISA strains

⁵*mecC* variant strains

In conclusion, the assay correctly identified 75 of the 77 MRSA strains tested with the BD MAX™ MRSA XT assay at 2-3X LoD. Two strains produced initially false negative MRSA result and were found to be MRSA positive after repeat testing from the SBT.

The assay detected:

- MRSA including:
 - MREJ types i, ii, iii, iv, v, vi, vii, ix, xiii, xiv, xxi (wild and mutant)
 - *mecA/mecC* variant gene
 - SCC*mec* types I, II, III, IV, V, VI, VII, VIII, XI
 - PFGE MRSA USA 100 to 800, 1000 and 1100
 - Strains isolated over 49 years (ranging from 1960 - 2009) representing temporal diversity
 - Strains representing 27 countries, geographical diversity
 - Strains displaying additional resistance to Vancomycin (VISA and VRSA)

f. Challenge Study:

An additional analytical study was carried out to evaluate the analytical performance of the BD MAX™ MRSA XT assay using a well characterized challenge strain panel. The objective of this study was to determine the assay results obtained with a challenge strain panel containing MRSA strains with high and low oxacillin MICs, including PFGE types USA 100 to 800, 1000, PFGE type IV/IBERIAN and *mecC* variant LGA251 strain, BORSA, MSSA and methicillin-resistant *Staphylococcus*

epidermidis (MRSE) strains using the BD MAX™ MRSA XT assay.

This study was performed in the framework of BD MAX™ StaphSR assay (K132822). The results from the BD MAX™ StaphSR assay were re-analyzed in the context of the BD MAX™ MRSA XT assay, considering MRSA as the only target to be reported.

The challenge strain panel used in this study was composed of 17 MRSA, four BORSA, one MRSE and five MSSA strains. All these strains were tested with FDA-cleared methods for determination of the MIC. The MRSA strains were all tested using the BD MAX™ MRSA XT assay at 2-3X LoD. The MSSA, BORSA and MRSE (non-MRSA) strains were all tested at high concentrations (approximately 10⁶ CFU/swab).

Table 13: Challenge Study Results Testing MRSA Strains at 2-3X LOD

	Sample ID	PFGE Type	MIC Level of Resistance	Assay Result Obtained with BD MAX™ MRSA XT Assay
MRSA	1	USA 100	Low	MRSA POS
	2		Low	MRSA POS
	3		Low	MRSA POS
	4	USA 200	High	MRSA POS
	5	USA 300	High	MRSA POS
	6		High	MRSA POS
	7		High	MRSA POS
	8		High	MRSA POS
	9		High	MRSA POS
	10	USA 400	High	MRSA POS
	11	USA 500	High	MRSA POS
	12	USA 600	High	MRSA POS
	13	USA 700	High	MRSA POS
	14	USA 800	Low	MRSA POS
	15	USA 1000	High	MRSA POS
	16	IBERIAN	High	MRSA POS
	17 ¹	ND	High	MRSA POS

¹*mecC* variant LGA251 strain

Table 14: Challenge Study Results Testing MRSE, MSSA, and BORSA Strains at 10⁶ CFU/swab or Higher

	Sample ID	Assay Result Obtained with BD MAX™ MRSA XT Assay
MRSE	1	MRSA NEG
MSSA	1	MRSA NEG
	2	MRSA NEG
	3	MRSA NEG

	4	MRSA NEG
	5	MRSA NEG
BORSA	1	MRSA NEG
	2	MRSA NEG
	3	MRSA NEG
	4	MRSA NEG

In conclusion, all strains tested as part of the Challenge Study exhibited the expected results with the BD MAX™ MRSA XT assay. All MRSA strains tested as part of the Challenge Study with the BD MAX™ MRSA XT assay exhibited MRSA POS results when tested at 2-3X LoD concentrations. The MRSE, BORSA and MSSA strains tested exhibited MRSA NEG results when tested at high concentrations.

g. Analytical Specificity:

The BD MAX™ MRSA XT assay was performed on samples containing high levels of non-target organisms and MSSA strains, using the BD MAX™ System, to demonstrate the specificity of the assay for detection of MRSA.

This study was performed in the framework of BD MAX™ StaphSR assay (K132822). The results from the BD MAX™ StaphSR assay were re-analyzed in the context of the BD MAX™ MRSA XT assay, considering MRSA as the only target to be reported.

The analytical specificity study testing included the following:

- Fifteen (15) empty cassette variant MSSA strains tested at $\geq 10^6$ CFU/swab
- Fifty-seven (57) strains of various non-staphylococcal species tested at a concentration of $\geq 10^6$ CFU/mL (except for *Cryptococcus neoformans* which was tested at 3×10^5 CFU/swab, the highest concentration achieved)
- Forty-five (45) Coagulase-Negative staphylococcal strains (CoNS) and Coagulase-Positive staphylococcal strains (CoPS) representing 28 species were tested at a concentration of 0.5 McFarland with the BD MAX™ MRSA XT assay.
- Fifty (50) MSSA strains tested at high concentrations ($\geq 10^6$ CFU/swab)
- Seventeen (17) viruses representing 12 different viral species tested at $\geq 10^5$ PFU/mL

Table 15: BD MAX™ MRSA XT Assay Analytical Specificity Study Results with Empty Cassette Variant MSSA Strains

Genera and Species	City/State of Origin	Country of Origin	MREJ Type	<i>mecA</i>	Assay Result Obtained with BD MAX™ MRSA XT Assay
<i>Staphylococcus aureus</i>	New Haven, CT	USA	i	-	MRSA NEG
<i>Staphylococcus aureus</i>	Charlottesville, Virginia	USA	ii	-	MRSA NEG

<i>Staphylococcus aureus</i>	Providence, Rhode Island	USA	ii	-	MRSA NEG
<i>Staphylococcus aureus</i>	Geneva	Switzerland	i	-	MRSA NEG
<i>Staphylococcus aureus</i>	Seattle, WA	USA	ii	-	MRSA NEG
<i>Staphylococcus aureus</i>	Terre Haute, IN	USA	ii	-	MRSA NEG
<i>Staphylococcus aureus</i>	Greifswald	Germany	i	-	MRSA NEG
<i>Staphylococcus aureus</i>	Leipzig	Germany	vii	-	MRSA NEG
<i>Staphylococcus aureus</i>	Leipzig	Germany	xiii	-	MRSA NEG
<i>Staphylococcus aureus</i>	Wurtzburg	Germany	ii	-	MRSA NEG
<i>Staphylococcus aureus</i>	-	Australia	vii	-	MRSA NEG
<i>Staphylococcus aureus</i>	Bolton	UK	ii	-	MRSA NEG
<i>Staphylococcus aureus</i>	Barnet, Herts	UK	i	-	MRSA NEG
<i>Staphylococcus aureus</i>	Barnet, Herts	UK	vii	-	MRSA NEG
<i>Staphylococcus aureus</i>	-	China	i	-	MRSA NEG

Table 16: BD MAX™ MRSA XT Assay Analytical Specificity Study Results with Various Non-*Staphylococcal* Species

Genera and species	Gram Stain ¹	Assay Result Obtained with BD MAX™ MRSA XT Assay
<i>Acinetobacter baumannii</i>	N	MRSA NEG
<i>Acinetobacter haemolyticus</i>	N	MRSA NEG
<i>Bacillus cereus</i>	P	MRSA NEG
<i>Bordetella pertussis</i>	N	MRSA NEG
<i>Candida albicans</i>	NA	MRSA NEG
<i>Candida albicans</i>	NA	MRSA NEG
<i>Candida guilliermondii</i>	NA	MRSA NEG
<i>Candida tropicalis</i>	NA	MRSA NEG
<i>Candida glabrata</i>	NA	MRSA NEG
<i>Citrobacter freundii</i>	N	MRSA NEG
<i>Citrobacter koseri</i>	N	MRSA NEG
<i>Corynebacterium aquaticus</i>	P	MRSA NEG
<i>Corynebacterium bovis</i>	P	MRSA NEG
<i>Corynebacterium flavesens</i>	P	MRSA NEG
<i>Corynebacterium genitalium</i>	P	MRSA NEG
<i>Cryptococcus neoformans</i>	NA	MRSA NEG
<i>Enterobacter aerogenes</i>	N	MRSA NEG
<i>Enterobacter cloacae</i>	N	MRSA NEG
<i>Enterococcus faecalis</i>	P	MRSA NEG
<i>Enterococcus faecium</i>	P	MRSA NEG
<i>Enterococcus flavesens</i>	P	MRSA NEG
<i>Enterococcus hirae</i>	P	MRSA NEG
<i>Enterococcus gallinarum</i>	P	MRSA NEG
<i>Escherichia coli</i>	N	MRSA NEG
<i>Escherichia coli</i>	N	MRSA NEG
<i>Escherichia coli</i>	N	MRSA NEG

<i>Haemophilus influenzae</i>	N	MRSA NEG
<i>Klebsiella oxytoca</i>	N	MRSA NEG
<i>Klebsiella pneumoniae</i>	N	MRSA NEG
<i>Lactobacillus crispatus</i>	P	MRSA NEG
<i>Lactobacillus reuteri</i>	P	MRSA NEG
<i>Lactobacillus acidophilus</i>	P	MRSA NEG
<i>Listeria monocytogenes</i>	P	MRSA NEG
<i>Micrococcus luteus</i>	P	MRSA NEG
<i>Moraxella catarrhalis</i>	N	MRSA NEG
<i>Neisseria gonorrhoeae</i>	N	MRSA NEG
<i>Neisseria meningitidis</i>	N	MRSA NEG
<i>Streptococcus anginosus</i>	P	MRSA NEG
<i>Streptococcus agalactiae</i>	P	MRSA NEG
<i>Streptococcus mitis</i>	P	MRSA NEG
<i>Streptococcus mutans</i>	P	MRSA NEG
<i>Streptococcus pneumoniae</i>	P	MRSA NEG
<i>Streptococcus pyogenes</i>	P	MRSA NEG
<i>Streptococcus salivarius</i>	P	MRSA NEG
<i>Streptococcus sanguinis</i>	P	MRSA NEG
<i>Streptococcus suis</i>	P	MRSA NEG
<i>Streptococcus sp.</i>	P	MRSA NEG
<i>Pasteurella aerogenes</i>	N	MRSA NEG
<i>Proteus mirabilis</i>	N	MRSA NEG
<i>Proteus vulgaris</i>	N	MRSA NEG
<i>Providencia stuartii</i>	N	MRSA NEG
<i>Pseudomonas aeruginosa</i>	N	MRSA NEG
<i>Pseudomonas fluorescens</i>	N	MRSA NEG
<i>Salmonella enterica</i> subsp. <i>Enterica</i>	N	MRSA NEG
<i>Serratia marcescens</i>	N	MRSA NEG
<i>Shigella sonnei</i>	N	MRSA NEG
<i>Yersinia enterocolitica</i>	N	MRSA NEG

¹Gram Stain Result: N = Gram Negative, P = Gram Positive, NA = Not Available

Table 17: BD MAX™ MRSA XT Assay Analytical Specificity Study Results with Various CoPS Species

Genera and Species	<i>mecA</i>	Country of Origin	Assay Result Obtained with BD MAX™ MRSA XT Assay
<i>Staphylococcus intermedius</i>	-	Unknown	MRSA NEG
<i>Staphylococcus delphini</i>	-	Unknown	MRSA NEG
<i>Staphylococcus lutrae</i>	Unknown	Unknown	MRSA NEG
<i>Staphylococcus lutrae</i>	Unknown	Unknown	MRSA NEG
<i>Staphylococcus pseudointermedius</i>	Unknown	Unknown	MRSA NEG
<i>Staphylococcus schleiferi</i>	Unknown	Unknown	MRSA NEG
<i>Staphylococcus schleiferi</i> subsp <i>coagulans</i>	Unknown	Unknown	MRSA NEG

Table 18: BD MAX™ MRSA XT Assay Analytical Specificity Study Results with Various CoNS Species

Genera and Species	<i>mecA</i>	Country of Origin	Assay Result Obtained with BD MAX™ MRSA XT Assay
<i>Staphylococcus arlettae</i>	+	Unknown	MRSA NEG
<i>Staphylococcus auricularis</i>	-	Argentina	MRSA NEG
<i>Staphylococcus capitis</i>	+	Canada	MRSA NEG
<i>Staphylococcus caprae</i>	+	Unknown	MRSA NEG
<i>Staphylococcus carnosus</i>	-	Unknown	MRSA NEG
<i>Staphylococcus chromogenes</i>	-	Unknown	MRSA NEG
<i>Staphylococcus cohnii</i> subsp. <i>urealyticum</i>	+	China	MRSA NEG
<i>Staphylococcus epidermidis</i>	+	USA	MRSA NEG
<i>Staphylococcus epidermidis</i>	+	Argentina	MRSA NEG
<i>Staphylococcus epidermidis</i>	-	USA	MRSA NEG
<i>Staphylococcus epidermidis</i>	+	Unknown	MRSA NEG
<i>Staphylococcus epidermidis</i>	+	USA	MRSA NEG
<i>Staphylococcus epidermidis</i>	+	USA	MRSA NEG
<i>Staphylococcus epidermidis</i>	+	USA	MRSA NEG
<i>Staphylococcus epidermidis</i>	+	Argentina	MRSA NEG
<i>Staphylococcus epidermidis</i>	-	Argentina	MRSA NEG
<i>Staphylococcus equorum</i>	-	Unknown	MRSA NEG
<i>Staphylococcus felis</i>	-	Japan	MRSA NEG
<i>Staphylococcus gallinarum</i>	-	Belgium	MRSA NEG
<i>Staphylococcus haemolyticus</i>	-	Argentina	MRSA NEG
<i>Staphylococcus haemolyticus</i>	+	China	MRSA NEG
<i>Staphylococcus haemolyticus</i>	+	Denmark	MRSA NEG
<i>Staphylococcus hominis</i>	-	Canada	MRSA NEG
<i>Staphylococcus hominis</i>	-	Canada	MRSA NEG
<i>Staphylococcus hominis</i>	+	Denmark	MRSA NEG
<i>Staphylococcus hominis</i> subsp. <i>hominis</i>	Unknown	USA	MRSA NEG
<i>Staphylococcus kloosii</i>	-	Unknown	MRSA NEG
<i>Staphylococcus lentus</i>	-	France	MRSA NEG
<i>Staphylococcus lugdunensis</i>	Unknown	France	MRSA NEG
<i>Staphylococcus pasteurii</i>	-	France	MRSA NEG
<i>Staphylococcus pulvereri</i>	-	Sweden	MRSA NEG
<i>Staphylococcus saprophyticus</i>	+	Canada	MRSA NEG
<i>Staphylococcus sciuri</i>	+	China	MRSA NEG
<i>Staphylococcus simulans</i>	+	Canada	MRSA NEG

<i>Staphylococcus warneri</i>	+	UK	MRSA NEG
<i>Staphylococcus warneri</i>	+	Unknown	MRSA NEG
<i>Staphylococcus xylosus</i>	-	Canada	MRSA NEG
<i>Staphylococcus xylosus</i>	-	Unknown	MRSA NEG

Table 19: BD MAX™ MRSA XT Assay Analytical Specificity Study Results with MSSA Strains

Genera and Species	City/State of origin	Country of Origin	Assay Result Obtained with BD MAX™ MRSA XT Assay
<i>Staphylococcus aureus</i>	Halifax	Canada	MRSA NEG
<i>Staphylococcus aureus</i>	Montreal	Canada	MRSA NEG
<i>Staphylococcus aureus</i>	Quebec	Canada	MRSA NEG
<i>Staphylococcus aureus</i>	Quebec	Canada	MRSA NEG
<i>Staphylococcus aureus</i>	Longueuil	Canada	MRSA NEG
<i>Staphylococcus aureus</i>	Ste-Foy	Canada	MRSA NEG
<i>Staphylococcus aureus</i>	Edmonton	Canada	MRSA NEG
<i>Staphylococcus aureus</i>	Toronto	Canada	MRSA NEG
<i>Staphylococcus aureus</i>	Vancouver	Canada	MRSA NEG
<i>Staphylococcus aureus</i>	Longueuil	Canada	MRSA NEG
<i>Staphylococcus aureus</i>	—	Canada	MRSA NEG
<i>Staphylococcus aureus</i>	—	Canada	MRSA NEG
<i>Staphylococcus aureus</i>	Montreal	Canada	MRSA NEG
<i>Staphylococcus aureus</i>	Rimouski	Canada	MRSA NEG
<i>Staphylococcus aureus</i>	Regina	Canada	MRSA NEG
<i>Staphylococcus aureus</i>	Québec	Canada	MRSA NEG
<i>Staphylococcus aureus</i>	Edmonton	Canada	MRSA NEG
<i>Staphylococcus aureus</i>	Ottawa	Canada	MRSA NEG
<i>Staphylococcus aureus</i>	Halifax	Canada	MRSA NEG
<i>Staphylococcus aureus</i>	Toronto	Canada	MRSA NEG
<i>Staphylococcus aureus</i>	—	Canada	MRSA NEG
<i>Staphylococcus aureus</i>	—	France	MRSA NEG
<i>Staphylococcus aureus</i>	—	Germany	MRSA NEG
<i>Staphylococcus aureus</i>	—	Germany	MRSA NEG
<i>Staphylococcus aureus</i>	—	Greece	MRSA NEG
<i>Staphylococcus aureus</i>	—	Ireland	MRSA NEG
<i>Staphylococcus aureus</i>	—	Ireland	MRSA NEG
<i>Staphylococcus aureus</i>	—	Israel	MRSA NEG
<i>Staphylococcus aureus</i>	—	Italy	MRSA NEG
<i>Staphylococcus aureus</i>	—	Italy	MRSA NEG
<i>Staphylococcus aureus</i>	—	Japan	MRSA NEG
<i>Staphylococcus aureus</i>	Rotterdam	Netherlands	MRSA NEG
<i>Staphylococcus aureus</i>	—	Poland	MRSA NEG
<i>Staphylococcus aureus</i>	—	Spain	MRSA NEG
<i>Staphylococcus aureus</i>	—	Sweden	MRSA NEG
<i>Staphylococcus aureus</i>	—	Sweden	MRSA NEG
<i>Staphylococcus aureus</i>	—	Switzerland	MRSA NEG
<i>Staphylococcus aureus</i>	—	Turkey	MRSA NEG

<i>Staphylococcus aureus</i>	—	UK	MRSA NEG
<i>Staphylococcus aureus</i>	Iowa	USA	MRSA NEG
<i>Staphylococcus aureus</i>	Atlanta	USA	MRSA NEG
<i>Staphylococcus aureus</i>	Connecticut	USA	MRSA NEG
<i>Staphylococcus aureus</i>	Wisconsin	USA	MRSA NEG
<i>Staphylococcus aureus</i>	—	USA	MRSA NEG
<i>Staphylococcus aureus</i>	—	USA	MRSA NEG
<i>Staphylococcus aureus</i>	New York	USA	MRSA NEG
<i>Staphylococcus aureus</i>	St-Louis	USA	MRSA NEG
<i>Staphylococcus aureus</i>	Washington	USA	MRSA NEG
<i>Staphylococcus aureus</i>	Chicago	USA	MRSA NEG
<i>Staphylococcus aureus</i>	Montreal	Canada	MRSA NEG

Table 20: BD MAX™ MRSA XT Assay Analytical Specificity Study Results with Various Viral Strains

Virus	Type/Strain	Concentration	Assay Result Obtained with BD MAX™ MRSA XT Assay
Adenovirus	Type 1	$1 \times 10^{6.62}$ TCID ₅₀ units/mL	MRSA NEG
Adenovirus	Type 7A	$1 \times 10^{8.73}$ TCID ₅₀ units/mL	MRSA NEG
Human coronavirus	OC43	$1 \times 10^{7.93}$ TCID ₅₀ units/mL	MRSA NEG
Human coronavirus	229E	$1 \times 10^{7.77}$ TCID ₅₀ units/mL	MRSA NEG
Cytomegalovirus	AD-169	$1 \times 10^{6.98}$ TCID ₅₀ units/mL	MRSA NEG
Enterovirus	NA	3.1×10^5 TCID ₅₀ units/mL	MRSA NEG
Epstein Barr Virus	B95-8	3.00×10^9 cp/mL ¹	MRSA NEG
Human influenza virus	A	4.6×10^5 PFU/mL	MRSA NEG
Human influenza virus	B	1.7×10^5 PFU/mL	MRSA NEG
Human parainfluenza	Type 1	$1 \times 10^{7.06}$ TCID ₅₀ units/mL	MRSA NEG
Human parainfluenza	Type 2	$1 \times 10^{7.29}$ TCID ₅₀ units/mL	MRSA NEG
Human parainfluenza	Type 3	4.27×10^5 TCID ₅₀ units/mL	MRSA NEG
Human metapneumovirus	NA	3.2×10^7 TCID ₅₀ units/mL	MRSA NEG
Measles	NA	$1 \times 10^{6.10}$ TCID ₅₀ units/mL	MRSA NEG
Mumps virus	NA	$1 \times 10^{9.44}$ TCID ₅₀ units/mL	MRSA NEG
Respiratory syncytial virus	Type B	5.37×10^5 TCID ₅₀ units/mL	MRSA NEG
Rhinovirus	1A	$1 \times 10^{6.10}$ TCID ₅₀ units/mL	MRSA NEG

¹The Epstein-Barr virus usually produces lysogenic infection and was therefore quantified in DNA cp/mL.

In conclusion, all organisms tested by the BD MAX™ MRSA XT assay in this Analytical Specificity Study at the concentrations indicated showed expected results. The observed analytical specificity in this study was 100%.

h. Potentially Interfering Substances:

An analytical study was performed to assess the potential inhibitory effects of biological and chemical materials that may be present on nasal swab specimens on the BD MAX™ MRSA XT assay.

This study was performed in the framework of BD MAX™ StaphSR assay (K132822). The results from the BD MAX™ StaphSR assay were re-analyzed in the context of the BD MAX™ MRSA XT assay, considering MRSA as the only target to be reported.

Biological and chemical substances occasionally used in the nares or found on nasal swab specimens were evaluated and are listed in the table below:

Table 21: Substances and Organisms Tested in the Potentially Interfering Substances Study

Brand Name or Description	State	Purpose	Manufacturer	Quantity or Percentage of Active Substance per Swab
Mucin, from bovine submaxillary glands	Liquid (once rehydrated)	Simulation of nasal secretion/mucus	EMB (Calbiochem®)	4.65×10^{-3} g
Dexamethasone Sodium Phosphate Ophthalmic Solution USP, 0.1% Dexamethasone Phosphate Equivalent (Sterile)	Liquid	Ophthalmic drops ¹	Bausch & Lomb Incorporated	7.5×10^{-5} g
Chloraseptic®	Lozenge (liquid once dissolved)	Oral anesthetic/analgesic lozenges	Manufactured for Prestige Brands, Inc.	Benzocaine: 9.0×10^{-6} g Menthol: 1.5×10^{-5} g
Taro-Mupirocin, Mupirocin Ointment USP, 2%	Gel	Topical nasal antibiotic	Taro Pharmaceuticals Inc.	2.7×10^{-2} g of Mupirocin USP 2%
Long Lasting Dristan® Nasal Mist	Nasal spray (liquid)	Temporary relief of nasal congestion	Wyeth Consumer Healthcare Inc.	3.8×10^{-5} g
Neo-Synephrine®	Nasal spray (liquid)	Nasal decongestant	Bayer Healthcare LLC	75 µL of Phenylephrine-HCl 0.5%
Equate® Nasal Spray Decongestant	Nasal spray (liquid)	Nasal Decongestant	Equate®	75 µL of Xylometazoline 0.1%
Beconase AQ®	Nasal spray (liquid)	Treatment of the nasal symptoms of seasonal or perennial rhinitis	GSK	3.6×10^{-5} g
Flunisolide Nasal Solution USP, 0.025%	Nasal spray (liquid)	Treatment of the nasal symptoms of seasonal or perennial rhinitis	Bausch & Lomb Incorporated	1.9×10^{-5} g
Nasacort® AQ	Nasal spray (liquid)	Treatment of the nasal symptoms of seasonal or perennial rhinitis	Sanofi-Aventis U.S. LLC	4.4×10^{-5} g

Rhinocort aqua®	Nasal spray (liquid)	Treatment of the nasal symptoms of seasonal or perennial rhinitis	AstraZeneca LP	4.3×10^{-5} g
Nasonex®	Nasal spray (liquid)	Treatment of the nasal symptoms of seasonal or perennial rhinitis	Schering Corporation	4.1×10^{-5} g
Fluticasone Propionate	Nasal spray (liquid)	Treatment of nasal allergy symptoms and nonallergic rhinitis	Hi-Tech Pharmacal Co., Inc.	3.8×10^{-5} g
Luffeel®	Nasal spray (liquid)	Homeopathic preparation used to treat hay fever	Heel Canada Inc.	Galphimia glauca and Luffa operculata: 7.5×10^{-3} g of each dilution Histaminum and Sulfur: 3.8×10^{-3} g of each dilution
Zicam® No-Drip Liquid® Nasal Gel™ Extreme Congestion Relief	Nasal gel	Relief of congestion due to the common cold, hay fever and upper respiratory allergies	Zicam LLC	3.7×10^{-2} g of oxymethazoline HCl 0.05%
Relenza®	Liquid (after resuspended)	Treatment and prophylaxis of influenza	GSK	6.4×10^{-3} g
Tobramycin	Liquid (after rehydrated)	Respiratory antibiotic	Sigma-Aldrich Corporation	4.5×10^{-3} g
Blood	Liquid	NA	NA	NA
FluMist®	Liquid	Influenza Vaccine Live, Intranasal	MedImmune	$10^{2.4-2.8}$ FFU (fluorescent focus units) of live attenuated influenza virus reassortants
<i>Staphylococcus epidermidis</i>	NA	Simulation of potential microbial interference	NA	1×10^5 CFU each
<i>Enterococcus faecium</i>				
<i>Enterococcus faecalis</i>				
<i>Escherichia coli</i>				
<i>Corynebacterium flavescens</i>				
<i>Moraxella catarrhali</i>				
<i>Staphylococcus hominis subsp. hominis</i>				

<i>Haemophilus influenzae</i>				
<i>Streptococcus pneumoniae</i>				

Most of the substances in the table above were available in a ready-to-use liquid or gel format and were used full strength in this study. Certain substances (e.g., Mucin, Chloraseptic[®], Relenza[®], Tobramycin) were rehydrated, dissolved or resuspended at a biologically or medically relevant concentration prior to use in this study. Fresh blood was obtained from a blood donor center.

For liquid substances, the volume tested was 75 µL since this volume represents the maximum volume that could theoretically be absorbed by a swab. For gel substances, swabs were coated with the substance. In both cases, the weight of each substance was considered as the maximum weight likely to be present on a nasal swab specimen. For substances available in a ready-to-use format, the actual amount of active ingredient used (g or %) was calculated based on documentation provided by the individual manufacturers.

MRSA negative samples and MRSA positive samples at 2-3 x LoD in simulated nasal matrix (Refer to the “Nasal Matrix and Simulated Nasal Matrix Equivalency Study” section of this decision summary for details) were tested with the highest amount of each substance or organisms likely to be found at the sampling site or on the nasal swab sample.

For each potentially interfering substance and for potential microbial interference assessment, at least 95% conforming assay results had to be obtained. In addition, equivalence had to be demonstrated between the conditions tested and the controls based on the statistical analyses as described below:

The two one-sided tests (TOST) procedure of Schuirmann (1987) was used to assess the equivalence of the SDPA means. Rejection of the non-equivalence hypothesis in favor of equivalence hypothesis at a significance level of 5% occurred only if the 90% confidence interval of the mean difference was contained completely within predetermined the equivalence margins below:

Table 22: Equivalence Margins for BD MAX[™] MRSA XT Assay

		Equivalence Margin
With and Without Potentially Interfering Substance	FAM SDPA (MRSA)	± 6%
	ROX SDPA (MRSA)	± 6%
	Cy5.5 SDPA (Neg)	± 4%

Testing results that did not comply with these acceptance criteria were indicative of a potentially interfering substance.

The Potentially Interfering Substances Study results demonstrated no reportable interference (based on the acceptance criteria described above) with any

microorganisms or chemical substances tested, except for Tobramycin, which showed inhibition in the BD MAX™ MRSA XT assay when tested at a concentration of 4.5×10^{-3} g/swab.

In conclusion, none of the potentially interfering microorganisms or chemical substances at the concentrations tested in this study interfered with the BD MAX™ MRSA XT assay, except for Tobramycin at 4.5×10^{-3} g/swab. Tobramycin is reported as an interfering substance in the product package insert.

i. Potential Microbial Competitor Study:

Low Loads of MRSA Co-Spiked with MRSE

An analytical study was performed to assess any potential competitive inhibitory effects of increasing concentrations of MRSE when co-spiked with low loads of MRSA.

This study was performed in the framework of BD MAX™ StaphSR assay (K132822). The results from the BD MAX™ StaphSR assay were re-analyzed in the context of the BD MAX™ MRSA XT assay, considering MRSA as the only target to be reported.

MRSA MREJ Type ii and MRSA MREJ Type iv strains were tested at 1-2X LoD in simulated nasal matrix (Refer to the “Nasal Matrix and Simulated Nasal Matrix Equivalency Study” section of this decision summary for details), with increasing concentrations of a co-spiked MRSE strain. The experimental testing conditions of the study were summarized in the three tables below:

Table 23: Testing Conditions for Assessing Potential Competitive Inhibitory Effects of Increasing Concentrations of MRSE when Co-spiked with Low loads of MRSA MREJ Type ii

Condition #	MRSA Strain	MRSA Strain Concentration in CFU/Swab	MRSE strain Concentration in CFU/Swab	MRSA to MRSE Ratio
1	MRSA MREJ Type ii	2.06E + 02	0	1:0
2		2.06E + 02	2.06E+02	1:1 x 10 ⁰
3		2.06E + 02	2.06E+03	1:1 x 10 ¹
4		2.06E + 02	2.06E+04	1:1 x 10 ²
5		2.06E + 02	2.06E+05	1:1 x 10 ³
6		2.06E + 02	2.06E+06	1:1 x 10 ⁴
7		2.06E + 02	2.06E+07	1:1 x 10 ⁵
8		2.06E + 02	1.74E+08 ¹	1:8.45 x 10 ⁵

¹Highest concentration achieved

Table 24: Testing Conditions for Assessing Potential Competitive Inhibitory Effects of Increasing Concentrations of MRSE when Co-spiked with Low loads of MRSA MREJ Type iv

Condition #	MRSA Strain	MRSA Strain Concentration in CFU/Swab	MRSE strain Concentration in CFU/Swab	MRSA to MRSE Ratio
1	MRSA MREJ Type iv	1.35E + 02	0	1:0
2		1.35E + 02	1.35E+02	1:1 x 10 ⁰
3		1.35E + 02	1.35E+03	1:1 x 10 ¹
4		1.35E + 02	1.35E+04	1:1 x 10 ²
5		1.35E + 02	1.35E+05	1:1 x 10 ³
6		1.35E + 02	1.35E+06	1:1 x 10 ⁴
7		1.35E + 02	1.35E+07	1:1 x 10 ⁵
8		1.35E + 02	1.35E+08	1:1 x 10 ⁶

To be considered to be “no competitive inhibitory effect observed” for this study, ≥ 95% of expected results had to be obtained when MRSA strains were tested at or near their respective LoD in the presence of MRSE, the potential microbial competitor.

The study results are presented in the tables below:

Table 25: Results of Assessing Potential Competitive Inhibitory Effects of Increasing Concentrations of MRSE when Co-spiked with Low loads of MRSA MREJ Type ii

Condition #	MRSA POS/MRSA NEG/UNR/Total	Conforming/ Total	% Conforming Result	IND Excluded
1	8/0/0/8	8/8	100%	0
2	8/0/0/8	8/8	100%	0
3	7/0/0/7	7/7	100%	1 ¹
4	6/0/0/6	6/6	100%	2 ¹
5	8/0/0/8	8/8	100%	0
6	7/1/0/8	7/8	87.5%	0
7	7/0/0/7	7/7	100%	1 ¹
8	8/0/0/8	8/8	100%	0

¹Sample(s) were excluded due to an “Indeterminate” (IND) result (i.e., Heater Warning or Error in Full Fill Check)

Table 26: Results of Assessing Potential Competitive Inhibitory Effects of Increasing Concentrations of MRSE when Co-spiked with Low loads of MRSA MREJ Type iv

Condition #	MRSA POS/MRSA NEG/UNR/Total	Conforming/ Total	% Conforming Result	IND Excluded
1	8/0/0/8	8/8	100%	0
2	8/0/0/8	8/8	100%	0
3	8/0/0/8	8/8	100%	0
4	8/0/0/8	8/8	100%	0
5	5/3/0/8	5/8	62.5%	0
6	7/1/0/8	7/8	87.5%	0
7	7/1/0/8	7/8	87.5%	0
8	8/0/0/8	8/8	100%	0

Table 27: Results of Assessing Potential Competitive Inhibitory Effects of Increasing Concentrations of MRSE when Co-spiked with Low loads of MRSA (MREJ types combined)

Condition #	MRSA POS/MRSA NEG/UNR/Total	Conforming/Total	% Conforming Result	IND Excluded
1	16/0/0/16	16/16	100%	0
2	16/0/0/16	16/16	100%	0
3	15/0/0/15	15/15	100%	1 ¹
4	14/0/0/14	14/14	100%	2 ¹
5	13/3/0/16	13/16	81.3%	0
6	14/2/0/16	14/16	87.5%	0
7	14/1/0/15	14/15	93.3%	1 ¹
8	16/0/0/16	16/16	100%	0

¹ Sample(s) were excluded due to an “Indeterminate” (IND) result (i.e., Heater Warning or Error in Full Fill Check)

In conclusion, competitive inhibitory effects were observed for an MRSA : MRSE ratio of $1 : \geq 1 \times 10^3$. These observed competitive inhibitory effects are reported in the product package insert.

Low Loads of MRSA Co-Spiked with MSSA

An analytical study was performed to assess any potential competitive inhibitory effects of increasing concentrations of MSSA when co-spiked with low loads of MRSA.

This study was performed in the framework of BD MAX™ StaphSR assay (K132822). The results from the BD MAX™ StaphSR assay were re-analyzed in the context of the BD MAX™ MRSA XT assay, considering MRSA as the only target to be reported.

MRSA MREJ Type iv, an MREJ type with one of the lowest LoDs of the assay, was tested at 1-2X LoD in simulated nasal matrix (Refer to the “Nasal Matrix and Simulated Nasal Matrix Equivalency Study” section of this decision summary for details), with increasing concentrations of a co-spiked MSSA strain. The experimental testing conditions of the study were summarized in the table below:

Table 28: Testing Conditions for Assessing Potential Competitive Inhibitory Effects of Increasing Concentrations of MSSA when Co-spiked with Low loads of MRSA MREJ Type iv

Condition #	MRSA Strain	MRSA Strain Concentration in CFU/Swab	MSSA strain Concentration in CFU/Swab	MRSA to MRSE Ratio
1	MRSA MREJ Type iv	1.35E + 02	0	1:0
2		1.35E + 02	1.35E+02	1:1 x 10 ⁰
3		1.35E + 02	1.35E+03	1:1 x 10 ¹
4		1.35E + 02	1.35E+04	1:1 x 10 ²
5		1.35E + 02	1.35E+05	1:1 x 10 ³
6		1.35E + 02	1.35E+06	1:1 x 10 ⁴
7		1.35E + 02	1.35E+07	1:1 x 10 ⁵
8		1.35E + 02	1.35E+08	1:1 x 10 ⁶

To be considered to be “no competitive inhibitory effect observed” for this study, $\geq 95\%$ of expected results had to be obtained when the MRSA strain was tested near the LoD in the presence of MSSA, the potential microbial competitor.

The study results are presented in the table below:

Table 29: Results of Assessing Potential Competitive Inhibitory Effects of Increasing Concentrations of MSSA when Co-spiked with Low loads of MRSA

Condition #	MRSA POS/MRSA NEG/UNR/Total	Conforming/Total	% Conforming Result	IND Excluded
1	24/0/0/24	24/24	100%	0
2	23/1/0/24	23/24	95.8%	0
3	24/0/0/24	24/24	100%	0
4	23/1/0/24	23/24	95.8%	0
5	23/1/0/24	23/24	95.8%	0
6	21/3/0/24	21/24	87.5%	0
7	24/0/0/24	24/24	100%	0
8	22/2/0/24	22/23	95.7%	1 ¹

¹One excluded sample due to an atypical curve in all channels caused by a bubble inside the PCR cartridge.

In conclusion, competitive inhibitory effect was observed for a MRSA : MSSA ratio of $1 : \geq 1 \times 10^4$. This observed competitive inhibitory effect is reported in the product package insert.

j. Carry-Over Study:

A study was conducted to evaluate the risk of carry-over contamination with the BD MAX™ MRSA XT assay on the BD MAX™ instrument.

This study was performed in the framework of BD MAX™ StaphSR assay (K132822). The results from the BD MAX™ StaphSR assay were re-analyzed in the context of the BD MAX™ MRSA XT assay, considering MRSA as the only target to be reported.

The testing panels used in this study were made of high positive MRSA members and negative members with or without simulated nasal matrix (Refer to the “Nasal Matrix and Simulated Nasal Matrix Equivalency Study” section of this decision summary for details).

Carry-Over without Simulated Nasal Matrix

The MREJ type with the lowest LoD in absence of simulated nasal matrix (MREJ Type iv MRSA strain) was used as the high positive panel member (8×10^7 CFU/swab). ID Broth was used as the negative panel member. Twelve (12) replicates of the high positive panel member and 12 replicates of the negative panel member were tested in each run; high positive and negative panel members were alternated sequentially in each run. Three operators performed three consecutive runs for a total of nine runs of 24 samples per run (i.e., 108 expected MRSA negative results).

Carry-Over with Simulated Nasal Matrix

The MREJ type with the lowest LoD in the presence of simulated nasal matrix (MREJ Type xiii MRSA strain) was used as the high positive panel member (5.3×10^7 CFU/swab). ID Broth was used as the negative panel member. Twelve (12) replicates of the high positive panel member and 12 replicates of the negative panel member were tested in each run; high positive and negative panel members were alternated sequentially in each run. Three operators performed three consecutive runs for a total of nine runs of 24 samples per run (i.e., 108 expected MRSA negative results).

The pre-determined acceptance criterion for this study is less than 2% false positive rate (point estimate) due to MRSA contamination.

Two MRSA false positive results were obtained during the carry-over study in absence of simulated nasal matrix. One MRSA false positive result was obtained during the carry-over study in presence of simulated nasal matrix.

Overall, from 210 reportable results out of 216 expected MRSA negative results, three false MRSA positive results were obtained (3/210, 1.4%; 95% CI, 0.5% - 4.1%) in this study due to carry-over contamination, which met the pre-determined acceptance criterion for this study.

k. Assay cut-off:

BD MAX™ MRSA XT assay cut-off values (see the table below) were determined in verification experiments in the framework of BD MAX™ StaphSR assay (K132822).

Table 30: MAX™ MRSA XT Assay Cut-off Values

Cut-off	FAM	ROX	Cy5.5
SDPA Min	10	10	25
SDPA Max	42	42	37
EP Min	156	300	236

The cut-offs of the BD MAX™ StaphSR assay were initially established through a series of internal analytical studies and verified through a clinical simulation as described below:

Cut-offs were initially set using an approach based on (but not limited to) the Process performance index (Ppk). The main idea behind cut-off determination was to vary the threshold values (cut-offs) considering the appropriate distribution for the PCR variables (EP and SDPA). The Ppk (the estimated proportion of false positive / negative results) was calculated in order to maximize sensitivity while minimizing non-specific amplification detection.

Briefly, the EP values of negative and positives samples were modeled using spiked simulated biological matrix samples. The interfering fluorescence from nearby channels (“cross-talk”) was also evaluated. Finally, the cut-offs were repositioned within a certain range and the final choice was based on expected false positive and negative proportions. These proportions were calculated using the distribution properties to ensure balanced and optimal sensitivity/specificity performance.

A positive result is obtained in FAM, or ROX channel when the fluorescence signal is higher than the EP cut-off and between the SDPA lower and upper cut-offs. However, only specific gene(s) required to correctly identify MRSA must be detected in corresponding channels. Moreover, cut-offs were set in order to allow the Sample Processing Control (SPC) to be predictive of Polymerase Chain Reaction (PCR) inhibition to avoid false-negative assay results.

Variability was included in the design of experiments to ensure that cut-offs values are suitable for true clinical specimens. Multiple instruments, reagents and simulated nasal matrix lots were therefore included in the study design.

The assay cut-offs selected were then verified with an experiment with 100 negative clinical specimens spiked with a low charge of MRSA MREJ Type ii and adjusted accordingly.

The final step of cut-offs determination was to verify whether cross-talk of amplification signal occurred.

Following these steps, preliminary cut-off values were refined for each channel.

Finally, a clinical simulation study involving 150 clinical samples was performed to verify the adequacy of the preliminary cut-offs.

These pre-determined preliminary cut-off values were validated again using the data collected during the clinical performance study.

2. Comparison studies:

a. *Method comparison with predicate device:*

Not applicable. Performance of BD MAX™ MRSA XT assay was evaluated against the reference method of culture in a prospective study.

b. *Matrix comparison:*

Not applicable.

3. Clinical studies:

a. *Prospective Study:*

Clinical performance characteristics of the BD MAX™ MRSA XT assay were determined in a multi-site prospective study in the framework of BD MAX™ StaphSR clinical investigation (K132822). The results of the BD MAX™ StaphSR assay were re-analyzed in the context of BD MAX™ MRSA XT assay, considering MRSA as the only target to be reported.

Three investigational sites participated in the study. To be enrolled in the study, patients had to be eligible for MRSA or SA testing according to institutional policies. Eligibility requirements for targeted screening as per clinical site policies included, but were not limited to: patients admitted into the particular healthcare system; patients admitted to the Intensive Care Unit; patients transferred to the Intensive Care Unit; pre-elective surgery patients; and patients being admitted from long-term care facilities. Specimens from patients previously enrolled in the study were excluded from the enrollment.

The Comparative Reference Method consisted of direct culture complemented by enriched culture. Enriched culture analysis was completed for all specimens that were negative for MRSA or SA by direct culture. Presumptive *S. aureus* colonies observed on selective (*S. aureus*) chromogenic medium were subcultured onto Blood Agar (BA). Identification was confirmed with an agglutination test, while methicillin resistance was confirmed by Cefoxitin disk (30 µg) diffusion susceptibility testing. Enrichment in Trypticase Soy Broth with 6.5% NaCl (TSB 6.5% NaCl) was completed in the event that MRSA or SA was not confirmed by the initial direct culture method. Turbid TSB 6.5% NaCl broth was used to inoculate additional chromogenic medium and BA plates; MRSA confirmation was performed as described above.

Performance against the Reference Method (Direct/Enriched Culture)

A total of 2451 specimens were enrolled in the study. Of those, 94 specimens were regarded as noncompliant per protocol criteria, and five fully compliant per protocol criteria specimens gave final non-reportable PCR results. A total of 2352 specimen results were used to determine the clinical performance of the BD MAX™ MRSA XT assay.

Compared to the Reference Method (Direct/Enriched Culture), the BD MAX™ MRSA XT assay identified 93.1% of the MRSA positive specimens and 97.5% of the MRSA negative specimens. For the population tested, this resulted in a Negative Predictive Value (NPV) of 99.5% and a Positive Predictive Value (PPV) of 73.2%.

Table 31: Results Obtained for MRSA with the BD MAX™ MRSA XT Assay in Comparison to the Reference Method

All Sites	Reference Method			
	MRSA	Positive	Negative	Total
BD MAX™ MRSA XT Assay	Positive	149	54 ^a	203
	Negative	11 ^b	2138	2149
	Total	160	2192	2352
Sensitivity: 93.1% (149/160) (95% CI ^c : 88.1%, 96.1%) Specificity: 97.5% (2138/2192) (95% CI ^c : 96.8%, 98.1%) PPV: 73.2% (95% CI ^c : 67.8%, 78.3%) NPV: 99.5% (95% CI: 99.1%, 99.7%)				

^a 12 of 54 MRSA False Positive BD MAX™ MRSA XT specimens were also found to be positive after repeat of Reference Method

^b 5 of 11 MRSA False Negative BD MAX™ MRSA XT specimens were also found to be negative after repeat of Reference Method.

^c Confidence Interval

Table 32: Site by Site Performance Obtained for MRSA with the BD MAX™ MRSA XT Assay in Comparison to the Reference Method

Clinical Sites	Prevalence ^a	Sensitivity with 95% CI ^b	Specificity with 95% CI ^b
Site 1	4.3% (41/960)	92.7% (38/41) (80.6%, 97.5%)	98.9% (907/917) (98.0%, 99.4%)
Site 2	5.8% (38/650)	86.8% (33/38) (72.7%, 94.2%)	98.5% (582/591) (97.1%, 99.2%)
Site 3	10.6% (81/765)	96.3% (78/81) (89.7%, 98.7%)	94.9% (649/684) (93.0%, 96.3%)
Overall	6.7% (160/2375 ^c)	93.1% (149/160) (88.1%, 96.1%)	97.5% (2138/2192) (96.8%, 98.1%)

^a Prevalence based on reference method only

^b Confidence interval

^c 2375 specimens were reference method compliant.

Performance against Direct Culture

A total of 2451 specimens were enrolled in the study. Of those, 2397 nasal swab specimens were found compliant at the specimen, direct culture and BD MAX™ MRSA XT assay level (i.e., 54 specimens were regarded as noncompliant per protocol criteria) and six fully compliant per protocol criteria nasal swab specimens gave non reportable results. A total of 2391 specimen results were used to determine the positive and negative percent agreement of the BD MAX™ MRSA XT assay against direct culture.

Compared to the direct culture method, the BD MAX™ MRSA XT assay identified 96.5% of the MRSA positive specimens and 96.9% of the MRSA negative specimens.

Table 33: Results Obtained for MRSA with the BD MAX™ MRSA XT Assay in Comparison to the Direct Culture Method

All Sites		Direct Culture		
		Positive	Negative	Total
BD MAX™ MRSA XT Assay	Positive	137	69	206
	Negative	5	2180	2185
	Total	142	2249	2391
Positive Percent Agreement: 96.5% (137/142) (95% CI ^a : 92.0%, 98.5%)				
Negative Percent Agreement: 96.9% (2180/2249) (95% CI ^a : 96.1%, 97.6%)				

^a Confidence interval

Table 34: Site by Site Performance Obtained for MRSA with the BD MAX™ MRSA XT Assay in Comparison to the Direct Culture Method

Clinical Sites	Positive Percent Agreement with 95% CI ^a	Negative Percent Agreement with 95% CI ^a
Site 1	100% (35/35) (90.1%, 100%)	98.6% (910/923) (97.6%, 99.2%)
Site 2	93.5% (29/31) (79.3%, 98.2%)	97.8% (585/598) (96.3%, 98.7%)
Site 3	96.1% (73/76) (89.0%, 98.6%)	94.1% (685/728) (92.1%, 95.6%)
Overall	96.5% (137/142) (92.0%, 98.5%)	96.9% (2180/2249) (96.1%, 97.6%)

^a Confidence interval

Unresolved, Indeterminate, Incomplete Rates

Out of 2399 nasal swab specimens compliant at the specimen and PCR level, tested with the BD MAX™ MRSA XT assay, 38 (1.6%) were reported as Unresolved, Indeterminate, or Incomplete after initial testing. Sixteen (16) (0.6%) were reported as Unresolved initially. The Unresolved Rate after repeat testing is 0.08% (2/2398) (one specimen was not retested since it had already been tested twice). Fourteen (14) (0.6%) were initially reported as Indeterminate. No result remained Indeterminate upon repeat (two specimens were not retested since they had already been tested twice). Eight (8) (0.3%) were initially reported as Incomplete. No result remained Incomplete upon repeat (one specimen was not retested since it had already been tested twice).

b. Retrospective Study:

Not applicable.

4. Clinical cut-off:

Not applicable.

5. Expected values:

In the BD MAX™ MRSA XT assay prospective clinical study a total of 2393 reportable results, from specimens compliant at the specimen and PCR levels, were obtained from

three geographically diverse sites and compared with Direct and Enriched culture. The study population was grouped into in-patient and out-patient categories. The number and percentage of MRSA positive cases, as determined by the BD MAX™ MRSA XT assay, are presented in the table below:

Table 35: Expected Values

Group	Total Number of Specimens ¹	BD MAX™ MRSA XT Assay	Positive MRSA Percentage
		Number of MRSA Positive	
In-patient	1683	178	10.6% (178/1683)
Out-patient	710	28	3.9% (28/710)
Total ¹	2393	206	8.6% (206/2393)

¹Total specimens based on compliant PCR results.

N. Instrument Name:

BD MAX™ System

O. System Descriptions:

1. Modes of Operation:

The 2nd generation BD MAX™ System fully automates cell lysis, nucleic acid extraction, PCR set-up, target amplification and detection. The system can process and analyze up to 24 specimens in one cartridge with two cartridges running simultaneously on the instrument. The system includes external and internal barcode reading, ensuring traceability throughout extraction and PCR process. The system includes a heater module, temperature sensors, and a fluorescence detection system with six optical channels.

2. Software:

FDA has reviewed applicant's Hazard Analysis and software development processes for this line of product types:

Yes ___X___ or No _____

3. Specimen Identification:

Specimens are labeled with a Barcode.

4. Specimen Sampling and Handling:

Not applicable. The nasal swab is manually inserted in the sample buffer tube, vortexed and placed into the system.

5. Calibration:

The system is calibrated by the manufacturer on-site as part of the installation procedure as well as during biannual preventive maintenance.

6. Quality Control:

Quality control is addressed for each specific assay to be run on the instrument (separately cleared).

P. Other Supportive Instrument Performance Characteristics Data Not Covered In The “Performance Characteristics” Section above:

Not applicable.

Q. Proposed Labeling:

The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

R. Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.